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Abstract 
This work is concerned with the synthesis and property investigation of a relatively new 
class of cyclometallated Ir(III) and Pt(II) complexes in which two metal centres are 
coordinated to a common heterocycle resulting in a rigid polymetallic assembly. Highly 
luminescent materials which can emit and absorb in a red region of the spectrum were 
targeted. 
   
There are three main parts of the thesis. The first part investigates how luminescent 
properties of the diplatinum systems are affected by the bridging ligand.  A series of novel 
mono- and dinuclear Pt(II) complexes has been prepared and their luminescent and redox 
properties investigated.  The main observation is that the introduction of the second metal 
centre leads to a substantial red-shift in absorption and emission. 
   
In the second part the role of changing the ligand substituents in a cyclometallated 
complex has been investigated to determine the extent to which luminescence is affected 
by the nature of the substituents.   A series of mono- and dinuclear Pt(II) complexes have 
been prepared using substituted pyrazine bridging ligands.  It was found that electron 
donating substituents such as –OMe in the benzene cyclometallating ring cause a red-
shift, while electron withdrawing substituents such as –F cause a blue-shift in emission.     
 
The final part of the work describes the synthesis of cyclometallated homometallic bis 
Ir(III) complexes.  A series of bis- Ir(III) complexes have been prepared using a terdentate 
cyclometallating N^C^N coordinating 1,3-di(2-pyridyl)benzene derivative as an auxiliary 
ligand.  It was found that the nature of the bridging ligand determines the overall stability 
of the complex.  Pyrimidine-linked systems were found to be the most stable, while 
pyrazine analogues readily photodecompose/isomerise. Pyridazine-linked systems lead to 
ionic complexes where one chloride ligand is shared by two Iridium metal centres.   
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1 Introduction  
Phosphorescent red and near-infrared emitters are desired for a variety of applications. 
For example they can be used in organic light-emitting diodes (OLEDs), which are 
emerging as the leading technology for a new generation of flat screen display 
technologies.  To be able to have this technology, highly efficient red (~650-700 nm), 
green (~500-550 nm) and blue (~450-470 nm) emitting compounds are required.  
Currently the red emitters have not been able to match up to the performance of the green 
emitters.  This is mainly due to the energy gap law, in that luminescence quantum yields 
have a tendency to decrease as the emission wavelength increases1.  Red emitters are 
also of interest in the development of luminescent sensors and probes for  bioimaging2.  In 
this wavelength range (650-950 nm), there is good tissue penetration and low 
autofluoresence. In addition IR or NIR wavelengths can pass through tissue without 
causing any cellular damage3.   
  
Initially, the development of luminescent metal complexes has been focused on 
ruthenium(II) complexes as they often absorb and emit in the red region due to the MLCT 
excited state.  More recently, cyclometallated platinum(II) and iridium(III) complexes are 
becoming more popular as they have somewhat superior photoluminescent properties 4.  
For example the quantum yield in solution of the best performing ruthenium(II) complexes 
is 4%, while many cyclometallated iridium(III) analogues emitting in the same region have 
quantum yields of 10-20%5.   
 
Cyclometallated complexes are organometallic compounds.  They are cyclometallated 
when a metal is covalently bound to a carbon atom of a polydentate ligand.  The 
remaining bonds come from coordinate bonds from heteroatoms such as nitrogen in the 
ligand6. 
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The following literature review first describes the synthesis of the main classes of highly 
luminescent cyclometallated Ir(III) and Pt(II) complexes. The review then goes on to 
describe in detail the photophysical properties of these complexes and the strategies 
employed to design red and infrared emitters. The review is concluded by discussing the 
application of red emitters in organic light emitting diodes and in bioimaging. 
 
1.1 Synthesis of cyclometallated complexes 
1.1.1 Synthesis of Pt(II) acac complexes 
 
Figure 1.1 Examples of Pt(II) acac complexes 
 
There have been several methods used to synthesise the Pt(II) complexes (examples of 
some Pt(II) complexes are shown in Figure 1.17), one of which is to heat the pro-ligand 
with potassium tetrachloroplatinate in 2-ethoxyethanol and water for 16 hours at 80oC.  
The chloride-bridged product is then heated with acetylacetone and sodium chloride for 16 
hours at 100oC to give the product8 (Scheme 1.1). 
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Scheme 1.1 Synthesis of Pt(ppy)(acac) 
Another method is to add the pro-ligand to a suspension of potassium tetrachloroplatinate 
in acetic acid.  The reaction mixture is stirred for 3-5 days at 80oC to give the 
chlorobridged dimer.  This dimer is then refluxed with acetylacetone and sodium 
carbonate in 2-ethoxyethanol for 12 hours to give the product (1.6) with a yield of 36 %9. A 
similar method is to heat the pro-ligand and potassium tetrachloroplatinate(II) in acetic 
acid at 70oC for 24 hours.  The resulting precipitate is then added to dimethylsulfoxide and 
refluxed for 10 minutes, precipitating [Pt(L)Cl(dmso)] (1.8).  This is then stirred with 
sodium acetylacetonate monohydrate and acetone at 50oC for 12 hours to give the final 
product (1.6)7 (Scheme 1.2).   
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Scheme 1.2 Similar routes to achieving synthesis of Pt(II) complexes 
An alternative method is to add a solution of platinum(II)chloride in benzonitrile to a 
solution of the pro-ligand (1.5) dissolved in diphenyl ether.  The solution is stirred at 190oC 
for 10 minutes then cooled, and acetone is added.  Acac and triethylamine are then added 
and stirred for 30 mins.  Hexane is added to precipitate the product (1.6) giving a yield of 
65 % (Scheme 1.3) 10. 
 
Scheme 1.3 Alternative synthesis of Pt(II) acac complexes 
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1.1.2 Synthesis of Ir(III) acac complexes 
 
Figure 1.2 Examples of Ir(II) acac complexes 
Figure 1.2 shows some examples of Ir(III) acac complexes1,11,12.  The first report of the 
synthesis of an iridium chloride-bridged complex was by Nonoyama in 197413.  A solution 
of Na3[IrCl6], 2-methoxyethanol and the pro-ligand (1.12) was stirred at room temperature 
for 8 hours then refluxed for a further 24 hours to give the chloride-bridged product (1.13) 
(Scheme 1.4).   
 
Scheme 1.4 First reported synthesis of Ir(II) complex 
More recent reports have described refluxing IrCl3.nH2O with the pro-ligand in 2-
methoxyethanol for 48 hours.  On cooling, water is added to precipitate the chloride-
bridged dimer14.  At present the most common method is to reflux IrCl3.nH2O with the pro-
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ligand (1.14) in a mixture of 2-ethoxyethanol and water (3:1) for 24 hours.  This gives the 
chloride-bridged dimer (1.15) which is then refluxed with acetylacetone and sodium 
carbonate in 2-ethoxyethanol for 12 hours to give the desired product (1.16) giving a yield 
of 45 % (Scheme 1.5) 15.  In my own work sodium acetylacetonate was used rather than 
acetylacetone and sodium carbonate as it was readily available. 
   
 
Scheme 1.5 Two routes to synthesis of Ir(III)(acac) complexes 
 
1.1.3 Synthesis of triscyclometallated Ir(III) complexes 
One of the simplest Ir(III) cyclometallated complexes is [Ir(ppy)3], the synthesis of which 
was first reported by Watts and co-workers in 198516,17.   
 
Scheme 1.6 shows the complex which is synthesised by refluxing iridium trichloride 
hydrate and 2-phenylpyridine (1.5) in a mixture of 2-ethoxyethanol and water (3:1 ratio).  
The yellow precipitate is then washed with ethanol and acetone.  The solvent is 
evaporated from these washings to give a yellow solid which is, after purification, [Ir(ppy)3] 
in a 10% yield (1.17) (synthesis A of Scheme 1.6).  However, the main product from this 
synthesis is 1.18 which, after purification, gives a 72% yield. 
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Scheme 1.6 Synthesis of [Ir(ppy)3] 
An alternative method is to dissolve tris(acetylacetonateo)-iridium(III), Ir(acac)3 and the 
pro-ligand (1.5) in glycerol and reflux for 6 hours.  1M aqueous hydrochloric acid is then 
added to precipitate the product (1.17),18,19 giving a yield of 45% (synthesis B of Scheme 
1.6).  
 
1.1.4 Synthesis of N^C^N Pt(II) complexes 
 
Figure 1.3 Example of a N^C^N Pt(II) complex 
An example of a N^C^N Pt(II) complex is shown in Figure 1.320.  An aqueous solution of 
potassium tetrachloroplatinate is added to a solution of the pro-ligand (1.20) in acetonitrile 
and the mixture is refluxed for 3 days to give the product (1.19)21 (synthesis A of Scheme 
1.7).  Another method is to reflux a mixture of the ligand (1.20) and potassium 
tetrachloroplatinate in acetic acid for 3 days the resulting precipitate is the product (1.19)22 
(synthesis B of Scheme 1.7).  
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Scheme 1.7 Two routes to synthesis of an N^C^N Pt(II) complex 
 
1.1.5 Synthesis of N^C^N Ir(III) 
Scheme 1.8  shows an N^C^N Ir(III) complex23.  The synthesis of N^C^N Ir(III) complexes 
are very similar to that of Ir(III) acac complexes in that the pro-ligand (1.21) is reacted with 
IrCl3.3H2O in a mixture of 2-ethoxyethanol and water (in a 3:1 ratio) to give the product 
(1.22) in a yield of 77 %24,23 (Scheme 1.8).  However unlike the synthesis of Ir(III) acac 
complexes, no further reactions are required.  
 
Scheme 1.8 Synthesis of an N^C^N Ir(III) complex 
 
1.2 Photophysical properties of cyclometallated complexes 
Iridium complexes used in electroluminescent devices are generally octahedral with a 3+ 
oxidation state11.  Iridium(III) polyimine complexes are luminescent, and the emissive state 
is dependent on the energy of the highest lying metal-centred orbital.  This in turn is 
determined by the number of anionic or cyclometallating donor atoms.  If there are no 
anionic or cyclometallating ligands bound to iridium(III), then emission occurs from the 
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ligand centred (LC) states.  For example [Ir(bpy)3]
3+ shows a highly structured emission at 
77 K with λem ~ 440 nm and a lifetime of ~80 µs25.  Iridium bis-terpyridine complexes are 
also luminescent at room temperature.  [Ir(terpy)2]
3+ shows an emission spectrum that is 
highly structured with λem at 458 nm for the highest energy peak26.  Emission is from an 
LC state but it is also likely to be mixed with metal-to-ligand charge transfer (MLCT) 
states.  The interplay between LC and MLCT emissive states is one reason for the 
investigation of such Iridium complexes as luminescent sensors. 
 
1.3 Strategies to achieve red shift 
1.3.1 Substitution in the cyclometallating and auxiliary ligands 
The HOMO and LUMO orbitals can be influenced by electron donating or withdrawing 
substituents.  Modifications to the ligands by adding substituents allow the emission 
energy to be tuned over a wide range.  This is mainly due to the HOMO and LUMO being 
localised on different parts of the molecule27.  A recent study looked at a series of Ir(III) 
complexes based on aryl(6-arylpyridin-3-yl)methanone ligands28 (Figure 1.4).   
 
Figure 1.4 The Ir(III) complexes were based on aryl(6-arylpyridin-3-yl)methanone ligands 
The authors incorporated 1-napthyl, 2-napthyl and fluorenyl groups into the ligand in this 
way, tuning of the emission was achieved.  Compared to (Bzppy)2Ir(acac) (1.25, Figure 
1.5) which showed an emission of  619 nm, the complexes showed an emission in the 
range of 621-668 nm giving a shift further into the red region.   
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Figure 1.5 (bis(2-phenyl-5-benzoyl- pyridine)Ir(acetylacetonate) or [(Bzppy)2Ir(acac)] 
Another paper29 showed that fluorinated analogues of a ligand can reduce triplet-triplet 
annihilation processes and also the sublimation temperature of these complexes is 
decreased, making them more desirable for applications such as OLEDs.  Introducing 
bulky groups can decrease the self-quenching of emitters at high doping levels.  Using 
fluorine ligands yields crystallisation-resistant materials that can be incorporated into 
single layer OLEDs, while expanding the π-conjugation of C^N ligands can result in 
enhanced device performance. 
 
Solutions of Ir(ppy)2(acac) exhibit green photoluminescence (λmax = 516 nm).  Tuning of 
this emission can be achieved by substitution of 2-phenylpyridine with other C^N binding 
ligands, from 512 nm to 612 nm30.  Changing the acac ligand results in a relatively minor 
shift.  A study of an Ir(pbt)2(acac) complex reported on the effects of modifications to the 
phenyl ring of the ligand31.  Laskar and Chen showed that fluorination at the 4-position of 
the complex results in a blue-shift of 16 nm, while fluorination at the 3-position of the 
complex results in a small red-shift and a tripling of photoluminescence quantum yield 
relative to the parent compound. 
 
When an electron donating group is introduced to the phenyl moiety of ppy, then the 
emission wavelength of the Ir(III)-ppy complex will be red shifted.  Recently, a series of 
Ir(III) complexes based on the 5-acetyl-2-phenylpyridine ligand was reported32.  Lee and 
co-workers found that all structures exhibited efficient red electroluminescence.  These 
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results suggest that complexes made from this ligand have excellent properties suitable 
for orange-red emitting materials for OLEDs.  The same group also noted that the position 
of an electron donating group on the ring can also affect the luminescence33.  Figure 1.6 
shows an iridium complex with a methyl group on the phenyl ring either para to the 
pyridine ring (complex 1.26) or ortho to the pyridine ring (complex 1.27).  It was found that 
1.27 was red-shifted by ~14 nm compared to 1.26.  It is thought that putting the methyl 
ortho to the pyridine ring causes a steric effect in the phenyl and pyridine rings.  The 
phenyl groups are then no longer planar with the central metal and the pyridine ring.  This 
gives a larger distorted angle and the energy gap in 1.27 becomes smaller compared to 
that of 1.26 after splitting from the ligand-iridium complex. 
 
 
Figure 1.6 The position of the electron donating group can also affect emission 
Red emitters can be achieved by adding electron-donating groups to the phenyl moiety 
and electron-withdrawing groups onto the pyridyl moiety of a metal complex.  The addition 
of electron-donating groups to the phenyl moiety leads to destabilisation of the HOMO, 
whereas the addition of electron-withdrawing groups to the pyridyl moiety reduces the 
energy of the LUMO, since it is generally localised on the π-orbitals of the pyridyl 
groups15.  However, one group has reported iridium complexes containing electron 
withdrawing groups on the phenyl moieties.  Three of these complexes (Figure 1.7) show 
bathochromic shifts compared to the parent complex [Ir(ppy)2(acac)] (1.9)
34. 
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Figure 1.7 The addition of electron withdrawing groups to the phenyl moiety of a complex can cause a 
red shift in emission 
Time-dependent density functional theory (TD-DFT) calculations showed that for the 
LUMOs there were large differences in the complexes.  The pyridyl ring π-orbitals 
contribute 63% to the LUMOs of 1.28, which is typical for Ir complexes.  However, the 
contribution for 1.29 was 44% and for 1.30 35%.  The π-orbitals of the pyridyl moiety are 
no longer the only contributor to the LUMO of 1.30; It is also distributed over the boron 
atom and the mesityl groups.  Therefore, for 1.30, the MLCT will be transferring electron 
density to the B(Mes)2 moiety rather than onto the pyridyl moiety which is typical of other 
iridium complexes.  The B(Mes)2 moiety will tend to stabilise the MLCT states strongly due 
to the “empty” pπ orbital.  This low energy MLCT state of 1.30 is responsible for the 
intense red phosphorescence. 
 
1.3.2 Increase in conjugation 
There are many examples of how extending the conjugation and, therefore, the π-system 
achieves a bathochromic (or red) shift in the wavelength (Figure.1.8).  A simple example 
shows how changing the pyridine of the ligand 2-phenylpyridine (ppy) to isoquinoline (piq), 
causes a bathochromic shift of ~100 nm.  Switching to isoquinoline lowers the LUMO of 
the complex, inducing the red shift35. 
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Figure.1.8 The addition of a phenyl ring can induce a red shift in emission 
These types of complexes are desirable as they are easy to synthesise, are thermally 
stable, and have good solubility in common organic solvents.  It is not enough for a 
complex to be a good emitter with high quantum yields; solubility is also important for use 
in OLED devices as the complexes can then be readily employed onto a substrate without 
the need for vacuum deposition methods which are expensive and inefficient.  More 
examples of red emitters are shown in Figure 1.9.  Once again the conjugated system of 
these complexes gave emissions in the red region. These complexes are synthesised by 
stirring a mixture of the ligand and iridium trichloride hydrate in ethoxyethanol at 120oC for 
24 hours.  The resulting precipitate is then filtered off and stirred with acac and sodium 
carbonate in 2-ethoxyethanol at 90oC for 12 hours.  The precipitate is then filtered off.36,11 
 
Figure 1.9 Examples of red emitters 
As conjugation is increased, emissions can be achieved that reach into the far red and 
even NIR of the spectrum.  Although, as will be discussed later, this does have limitations 
in that there is a point where the effect of conjugation breaks down and has a detrimental 
effect on emission.  Examples using dendrimers have achieved emissions as long as 693 
nm (Figure 1.10)5.  Dendrimers have a central, light-emitting core with an interior 
branched structure and an exterior surface containing functional groups, in this case, to 
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provide solubility.  Potential advantages over other conjugated complexes include 
improved solubilty by using appropriate surface groups, also the intermolecular 
interactions can be fine-tuned by the type and level of dendrons used. 
 
Figure 1.10 First generation dendrons 
 
It is also possible, by modification of the quinoline portion of a compound, to further 
enhance the red shift towards and into the NIR region of the spectrum (Figure 1.11).  
Extension of the π-electron delocalisation of the aromatic ligand leads to a shortened 
energy gap between the ground and lowest excited states1. 
  
Figure 1.11 Modification of the quinoline portion gives a NIR emission 
The positioning of additional phenyl rings on either the phenyl or pyridyl moieties of the 
ligand can also influence the wavelength of emission for a complex.  The complex shown 
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in Figure.1.8, 1.38 gives an emission at 618 nm.  If the position of the additional ring is 
moved (1.39) then there is a slight hypsochromic shift and emission is 597 nm37(Figure 
1.12). 
 
Figure 1.12 The position of the additional ring affects the emission 
The same can also be said when adding an additional ring onto the phenyl moiety of the 
complex.  A further increase of the conjugation gives an even greater red shift, but again 
just how much is dependent on the position of the ring38. Figure 1.13 shows how the 
addition and position of an additional ring to the phenyl moiety can give a red shift of up to 
60 nm. 
 
Figure 1.13 Addition and position of an additional ring gives a bathochromic shift 
A red shift can also be achieved by incorporating an additional nitrogen into the pyridyl 
ring.  For example, changing the pyridyl moiety to pyrazine can achieve a red shift of 60-
80 nm.  This is mainly due to a lowering of the LUMO of the pyrazine derived ligand39.  In 
the example shown in Figure 1.1439, the complexes are NIR emitters giving emissions of 
775 and 855 nm. 
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Figure 1.14 NIR emitters are more red shifted with the addition of an extra nitrogen into the complex 
As already stated, an increase of the conjugation of the ligand can increase the 
wavelength of emissions, but where the increase in conjugation on the ligand occurs is 
also a contributing factor.  Figure 1.15 shows copolymers based on carbazole-alt-fluorene 
as a main chain with an iridium complex as a side group.  The side groups differ only in 
the position of the additional phenyl ring.  The shortest wavelength has the phenyl ring 
attached to the phenyl moiety of the ligand (1.42)40. 
 
Figure 1.15 The position of the extra phenyl ring can also effect emission 
 
1.42 
415 
 
1.43 1.44 
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Figure 1.16 shows how replacement of a methyl group at the pyridyl moiety by nitrogen 
gives a pyrazine moiety.  The electronegative nitrogen causes a significantly decreased 
LUMO.  The energy gap of this complex is then reduced since the HOMO of the complex, 
which is mainly located at the phenyl moiety of the complex and is electron rich, remains 
unchanged.  Attachment of an extra aromatic ring to the pyrazine moiety increases the π-
conjugation of the complex, therefore reducing the energy gap further.  In this way tuning 
of the complexes to emit in the red region can be achieved14. 
 
Figure 1.16 Ligand tuning to achieve a red shift in emission 
There does come a point when increasing the conjugation of a complex starts to have a 
detrimental effect on the emission.  A recent study reports on the synthesis of a series of 
oligothienylpyridines as both platinum(II) and iridium(III) complexes with increasingly 
conjugated systems41.  Figure 1.17 shows some of the complexes synthesised with both 
1.49 and 1.52 emitting far into the red/NIR region.  The addition of a thiophene ring, 
therefore increasing the conjugation further, leads to a blue shift in emission.  This blue 
shift is due to the decrease in the participation of the metal d orbitals if there is too much 
conjugation and the HOMO decreases.  This leads to an increasing energy gap which 
also reduces the rate of intersystem crossing.  As a consequence, fluorescence is also 
observed and the intensity of the phosphorescence decreases. 
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Figure 1.17 Increasing conjugation too much causes a hypsochromic shift in emission 
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1.3.3 Excimers of NCN Ir(III) 
Complexes with two bidentate N^C ligands are usually synthesised by a reaction that 
introduces both N^C ligands at the same time to the metal ion, followed by the addition of 
an auxiliary ligand.  This means that two differently substituted cyclometallated ligands 
cannot be investigated by this method.  However, by using one terdentate 
cyclometallating ligand, one bidentate cyclometallating ligand and a monodentate 
cyclometallating ligand, the effects on emission of substitution in two different 
cyclometallated ligands can be investigated.  Brulatti and co-workers investigated a series 
of Ir(III) complexes based on 1,3-di(2-pyridyl)benzene23.  Figure 1.18 shows two Ir(III) 
complexes from the study which both emit in the red region of the spectrum.  Addition of 
fluorine groups onto the ppy ligand (1.55) results in a blue shift of 21 nm.  The electron-
withdrawing fluorine atoms decrease the delocalised electron density in the aromatic ring. 
 
Figure 1.18 N^C^N coordinated complexes.  Fine tuning can be achieved through substitution on the 
bidentate cyclometallating ligand. 
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The TD-DFT data for these complexes show that the terdentate cyclometallating ligand 
contributes to both the HOMO and the LUMO, whereas the bidentate cyclometallating 
ligand shows very little role in the LUMO.  Compared to tris-bidentate Ir(III) complexes, 
these complexes give a wider diversity of substitution and so give further opportunities to 
manipulate their emissive properties. 
 
In order to achieve the desired coordination mode, Wilkinson and co-workers24 describe 
how the addition of methyl substituents into the ligand at the C4 and C6 positions can 
avoid competitive cyclometalation and the desired complex can be achieved.  They 
describe a number of iridium complexes, not all of which have good emissive properties. 
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Figure 1.19 Structures of the Iridium complexes containing the N^C^N bound ligand dpyx 
Figure 1.19 shows the Iridium complexes described, with complexes 1.59 and 1.60 being 
very weakly emissive at room temperature.  It was also noted that they were a pale yellow 
colour compared to the other complexes which were a strong orange colour.  Complex 
1.58 was shown to be very strongly emissive. 
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Figure 1.2042 shows some of the complexes synthesised by Obara and co-workers with 
the general formula [Ir(N^C^N)(ppy)X]42.  They give another example of how tuning of the 
monodentate and/or bidentate ligands can affect the emission.  Fluorination of the 
complexes causes a slight blue-shift in emission of 9 nm in compound 1.65 compared to 
compound 1.66.  The blue-shift is greater between compound 1.67 and 1 with a shift of 15 
nm.  
Compound 1.68 is more red-shifted than compound 1.66 by 29 nm as cyanide is a much 
stronger electron withdrawing group than chlorine.  Comparing all four complexes, the 
monodentate ligand has a bigger effect on the luminescent properties than the bidentate 
ligand, in this case. 
 
Figure 1.20 Mixed-ligand Ir complexes [Ir(N^C^N)(ppy)X] and their emission spectra 
 
 
 
 
Emission spectra of Ir complexes 1.65 (blue), 1.66 (green), 1.67 (orange) and 
1.68 (red) in CH2Cl2-toluene (1:1 v/v) at 77 K 
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1.3.4 Polymetallic assemblies 
Most reports so far have involved complexes synthesised using platinum(II) or iridium(III) 
as the only metal present in the complex.  Recently, complexes have been synthesised 
using both platinum(II) and iridium(III) in the same complex43. 
 
Figure 1.21 Platinum(II), iridium(III) and polymetallic complexes 
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Figure 1.21 shows the complexes synthesised for this work.  The introduction of the 
additional metal was found to lead to a red shift in absorption and emission.  Figure 1.2243 
shows the UV-visible absorption spectra of the complexes.  It was concluded that the 
multimetallic complexes behave very differently to their monometallic counterparts.  This 
is mostly due to the conjugation of the LUMO across the entire aromatic ligand.  The 
pyrimidine acts as a bridge of communication.  The metallic units do not retain their 
separate identities, which are found to be the case with many other multimetallic systems.  
For instance, it can be seen that the absorption and emission of an iridium(III) complex 
can be greatly red shifted with the addition of platinum(II) ions. 
 
Figure 1.22 UV-visible absorption spectra of the metal complexes in CH2Cl2 solution at 298 K 
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1.3.5 Auxiliary ligand 
It is important for applications such as OLEDs and cell imaging that the metal complex 
has a good solubility.  This can be achieved by including bulky groups on the ligand.  
When they are introduced to the auxiliary ligand then solubilty can be increased without 
affecting the luminescence of the complex.  Figure 1.23 shows an iridium complex 
synthesised using three different auxiliary ligands – 1,3-bis(3,4-dibutoxyphenyl)propane-
1,3-dionate-o,o (bdbp, 1.73), dipivaloylmethanate (dpm, 1.74), acetylacetonate (acac, 
1.75).  They all emit at the same wavelength, showing that, in this case, the auxiliary 
ligand does not affect luminescence.  It was found that 1.73 had an increase in quantum 
yield compared to 1.74 and 1.7544.  Replacing acac and dpm with bdbp does enhance the 
phosphorescence quantum efficiency of these systems. 
 
 
Figure 1.23 Complexes showing that luminescence is not affected by the auxiliary ligand 
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1.4 Organometallic Complexes and Cell Imaging 
1.4.1 Cells 
The Cell is the fundamental building block of all living organisms.  It is the simplest 
collection of matter that can live.  There are two types of cell; prokaryotic or eukaryotic.  
Prokaryotic cells are those without membrane-bound nuclei and are only found in bacteria 
or archaea.  Eukaryotic cells are those with membrane-bound nuclei and are found in 
animals, plants, fungi and protists.  Eukaryotic cells are generally larger and more 
complex.  They contain membrane-bound organelles, which are lacking in prokaryotic 
cells.  Organelles have a specialised structural or functional role within the cell, such as 
the nucleus, lysosome or mitochondria. 
 
Figure 1.24 Figure of an animal cell taken from http://waynesword.palomar.edu/lmexer1a.htm 
 
Most cells are between 1 and 100 µm in diameter so to understand how a cell functions, 
cell biologists need microscopes to be able to view them.  There are various techniques in 
light microscopy used to view a cell, such as brightfield or phase-contrast.  Brightfield 
passes light directly through either a stained or unstained specimen but this technique has 
little contrast.  Amplifying variations in density in a specimen using phase-contrast can be 
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useful for examining living, unpigmented cells. If specific molecules within the cell are to 
be studied then fluorescent cell imaging is a very important tool45. 
1.4.2 Cell Imaging 
The application and use of phosphorescent heavy-metal complexes as bioimaging probes 
is a relatively new research field that is showing rapid development46.  To date there are  
few studies that involve organometallics.  These complexes, which contain one or more 
metal-carbon bonds, have a number of properties required to make a useful fluorophore 
for applications in cell imaging. 
 
Fluorescent cell imaging is important for diagnostics and biomedical research.  This 
method involves excitation of the cell sample and detection of the emitted light.  This 
detection is usually done by confocal microscopy2.  Confocal microscopy is a very 
powerful technique as it eliminates interference from reflected/diffracted light.  It allows 
filtering by depth of field which allows ‘slices’ of a sample to be recorded separately.  
These images can then be combined to build up a 3D image of the sample46.  Confocal 
microscopy has a much greater sensitivity than normal microscopy as only emitted light is 
observed rather than the reflected or transmitted light. 
 
Cell imaging uses fluorescence to highlight the important structures within the cell.  Some 
parts of a cell are already fluorescent, however the non-fluorescent areas of the cell can 
also be observed with the application of a commercially available fluorescent dye47.  Each 
dye is targeted to a different part of the cell and emits at different wavelengths.  By 
applying more than one dye to a cell, confocal microscopy can be used to collect images 
of the different areas of the cell, which can then be brought together as one 3D image 
highlighting all of the important areas of the cell. 
 
When using these dyes, there is a need to differentiate between the autofluorescence 
(natural emission of light by biological structures) of the biological species and the 
fluorescence derived from the dye.  It can be difficult to distinguish clearly between the 
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areas that have accumulated the dye and those that are showing autofluoresence.  There 
are two techniques that can be used to combat this problem, namely co-localisation and z-
scans.  Co-localisation is the technique of applying two dyes simultaneously, one of which 
will be suspected of targeting a certain part of the cell.  The second dye will have different 
emission properties but be well known to target the part of the cell in question.  The 
images from the two dyes are then overlaid and can then be measured.  From this the 
specificity of the new dye for its desired target can be determined.  Confocal microscopy is 
then used to acquire images, which represent slices through the depth of the cell (the z-
dimension).  Z-scans are used to ensure that the new dye has penetrated the interior of 
the cell rather than just associating with the surface (Figure 1.2548). 
 
Figure 1.25 Confocal fluorescence Z-section live cell images of AuNP-2 (20 μM) with Hela cells 
showing luminescence in three dimensions. Shown is the image obtained with cells costained with 
nuclear stain DAPI (blue) and AuNP-2 (red). Scanning from left to right. 
There are several characteristics required of a successful fluorophore to be used in cell 
imaging.  The optimal excitation wavelength for a fluorophore should be in the deep red or 
near-infrared range (650-950 nm).  In this range there is both good tissue penetration and 
low autofluoresence. In addition IR or NIR wavelengths can pass through tissue without 
causing any cellular damage.  Fluorescent brightness is another consideration.  The 
brighter the emission from the compound, the less excitation intensity is needed3. 
 
The desired photophysical characteristics for a fluorophore are - 
-excitation and emission at non-damaging wavelengths 
-large Stokes shift 
-resistant to photobleaching 
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If there is a large enough difference in wavelength between the two modes of 
fluorescence then autofluorescence can be filtered out.  This is highly likely if the 
fluorophore has a large Stokes shift.  The Stokes shift is the difference in wavelength 
between the absorbed and emitted light.  Typically, the Stokes shift involved in 
autofluoresence is small2.    Photobleaching is the photochemical degradation of 
fluorophores.  Most organic fluorophores suffer from photobleaching in long-term 
observation49.  
 
Figure 1.26 Jablonski diagram taken from http://www.files.chem.vt.edu/chem-
ed/quantum/jablonsk.html 
Heavy metal complexes can have the stability and photophysical properties required of a 
cell imaging agent.  These triplet emitters tend to have a large Stokes shift.  They also 
have long luminescence lifetimes due to the forbidden nature of the emission from triplet 
states.  The presence of heavy atoms facilitates inter-system crossing by spin-orbit 
coupling50.  Figure 1.26 shows a Jablonski diagram which illustrates the molecular 
electronic and vibrational energy levels.  Fluorescent complexes are excited to the singlet 
state and quickly relax back down to ground state.  Phosphorescent complexes are 
excited to singlet state and can then undergo intersystem crossing and become a triplet 
state.  Return to the ground state is forbidden. 
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The long luminescent lifetimes make these complexes suitable for use in time-resolved 
emission imaging microscopy (TREM).  This technique uses time-scales from hundreds of 
nanoseconds to microseconds and allows for time-gated experiments that can distinguish 
the target fluorescence from short-lived autofluorescence51.  Images are obtained using a 
time-gated camera at different time delays after the excitation pulse (Figure 1.27). 
 
Figure 1.27 Diagrammatic illustration of the concept of time gating to eliminate short-lived background 
fluorescence and of time slicing to monitor the temporal decay of emission and obtain quantitative 
data. 
For example, images of cells pre-treated with a Pt(II) complex in the presence of 
fluorescein dianion (whose emission serves as a model of short-lived background 
fluorescence) were taken.  Figure 1.2851 shows that the image on the left, taken 
immediately after the excitation pulse, is dominated by the fluorescein emission.  
However, when the camera was activated after a delay of 10 ns, the cells could be 
visualised using the long-lived emission from the Pt(II) complex51. 
 
Figure 1.28 Time-gated cellular imaging: live CHO cells preincubated with [PtL1Cl], imaged in the 
presence of solution of fluorescein in 1M NaOH. The images were taken at 0 ns (Left) and at 10 ns 
(Right) delays after the 355-nm laser pulse. (Scale bar: 10 μm.) 
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Multiphoton microscopy (MPM) is a form of laser-scanning microscopy that is proving 
useful for imaging thick tissue and live animals52.  Two-photon excitation uses two 
photons of equal energy from the same laser.  The photons interact with a molecule and 
produce an excitation, which is the equivalent to the absorption of a single photon but has 
twice the energy. 
In addition to above-mentioned photophysical characteristics, to be useful in cell imaging 
a fluorophore must ideally be: 
-able to enter cells 
-able to localise in desired compartments 
-non-toxic and stable 
To be a successful imaging agent, it is important to have a good balance of lipophilicity 
and solubility. Cell membranes are composed of lipids and so highly polar species can be 
poorly uptaken by cells.  On the other hand, the medium in which the cells are incubated 
is an aqueous buffer, so it is important to have sufficient solubility to be available for 
uptake by cells.  Localisation is a useful property to be able to target a specific area inside 
the cell (Figure 1.2946).  This could be controlled by either a chemical reaction with a 
species present within the organelle or by matching charges, polarity and lipophilicity with 
the target.  It is also desirable to have a compound which has low toxicity during the 
experiment so kinetic inertness is important2. 
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Figure 1.29 Localisation of the d
6
 species in cells 
 
  
The charge of a species is important for cellular uptake.  Cells have a negative surface 
charge so heavy-metal complexes with a positive charge can easily interact with and enter 
living cells.  There are many examples of Ir(III) and Ru(II) complexes with a positive 
charge that can enter living cells53.  
 
A suitable hydrophobicity can also help heavy metal complexes to enter living cells.  One 
example54 shows the cellular uptake of iridium complexes.  The cellular uptake efficiencies 
increase with the enhancement of the lipophilicity.  Ideally, such molecules are 
amphipathic; part of the molecule needs to be hydrophilic for solubility in water and part of 
it needs to be lipophilic for cell permeation.  Excess lipophilicity can reduce the efficiency 
of cellular uptake.  Lipophilicity can be enhanced by lengthening the alkyl chains and 
conjugated skeleton55. 
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Figure 1.30 Structures used by Lo & Lau (2008).  The table of log P values show a correlation between 
alkyl chain length and lipophilicity 
Figure 1.30 shows that lengthening the alkyl chain in a series of complexes can 
substantially enhance their lipophilicity, shown by the larger log P values of the C18 
complexes compared to the C2 complexes. 
 
 
 
 
 
 
 
 
 
Complex log Po/w 
1a 8.79 
1b 4.42 
1c 0.44 
2a 6.52 
2b 3.94 
2c -0.34 
3a 9.89 
3b 5.34 
3c 2.01 
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1.4.3 Cyclometallated platinum(II) complexes in bioimaging 
There are very few examples of cyclometallated platinum(II) complexes being used in cell 
imaging.  Most work to date has involved iridium(III) complexes.  Platinum(II) complexes 
are found to have useful properties, and some of them can be used for protein staining.  
This is of particular importance in biochemistry as common methods such as Bradford, 
bicinchoninic acid and Lowry assays are hampered by the interfering agents found in the 
sample preparation buffers.  They also need large sample volumes, have limited range 
and exhibit responses which are affected by the structure of proteins, the amino acid 
sequence and the isoelectric point56. 
 
Reports suggest57 that Pt complexes can be used to act as luminescent probes.  When 
incubated with HeLa cells, it was found that the [Pt(C^N^N)Cl] complex shown in Figure 
1.31 had luminescent signals with different intensities localised in different compartments 
of the HeLa cells.  This platinum complex was mostly distributed inside the cytoplasm.  
Functionalisation of the cyclometalating ligand with pendant moieties of different 
bioactivities and functionalities can be achieved, and with these pendants, a series of 
biolabelling and biosensing probes for different sub-cellular targets can be developed56. 
 
Figure 1.31 Structure of platinum complex and images showing luminescence (left), brightfield 
(middle) and overlaid (right) HeLa cells with the Pt complex. 
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Platinum(II) complexes have been shown to be capable of 2-photon excitation58.  The 
platinum(II) complex shown in Figure 1.32 has multiphoton luminescence, fast 
bioaccumulation in live cells and relatively low cytotoxicity. 
 
Figure 1.32 Chemical structure of platinum (II) complex capable of 2-photon excitation 
In a later paper, Lam and co-workers added a cationic triphenylphosphonium pendant 
linked together by a C-5 methylene spacer (1.78, Figure 1.33).  This Pt(II) complex has an 
affinity for nuclear or nucleolar proteins within the organelle.  They demonstrated that 
functionalization of the cyclometallating ligand with different moieties can be achieved; 
thus, a range of compounds can be generated with differing sub-cellular targets59. 
 
Figure 1.33 Cationic triphenylphosphonium pendant linked together by a C-5 methylene spacer 
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1.4.4 Cyclometallated iridium(III) complexes in bioimaging 
There are many examples of cyclometallated iridium(III) complexes exhibiting intense and 
long-lived emission in the visible region.  This enables them to function as luminescent 
sensors60.  For example Huang and co-workers reported on the synthesis of an iridium(III) 
complex that can be used as a sensor for homocysteine61.  It’s thought that the aldehyde 
group of the iridium (III) complex reacts with the amino group of the homocysteine (Figure 
1.34).  When homocysteine is added to the complex, a colour change from orange to 
yellow is observed.  The emission colour also changes from deep red to green.  This 
property is unique to homocysteine over other amino acids. 
 
Figure 1.34 Possible reaction of the iridium (III) complex with homocysteine 
Complexes of the general formula [Ir(ppy2(N^N)]
+ are attractive for cell imaging purposes 
as they are monocationic, which assists with membrane potential-driven uptake2.  One of 
the first reports of iridium complexes in cell imaging came from Yu and co-workers.  They 
demonstrated that fluorinated cyclometallates (Figure 1.35) were efficiently taken up by 
HeLa cells and localised in the cytoplasm62.  HeLa cells are human cervical cancer cells.  
They were initially taken from a woman named Henrietta Lacks in 1951 and have been 
continuously cultured in the lab since.  There are lots of different strains of HeLa cells now 
used for furthering research in understanding cancer, HIV/AIDS and cells in general63. 
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Figure 1.35 Chemical structures of iridium(II) complexes reported by Yu and co-workers 
Yu and co-workers suggested that the fluorinated units are essential for increased 
lipophilicity and, therefore, assisting with cellular uptake.  However, subsequent studies 
have suggested that iridium cyclometallates themselves are of high enough lipophilicity to 
ensure efficient cellular uptake.  There tends to be non-specific localisation throughout the 
cytoplasm2, but there are some examples of complexes being more localised.  Zhang and 
co-workers reported an iridium complex (Figure 1.36) that has an extended conjugated 
aromatic system suitable for DNA intercalation.  Figure 1.36 shows fluorescence laser-
scanning confocal microscopy images of fixed MDCK cells treated successively with 
fibrillarin antibody, Alexa 633 antirabbit IgG antibody, and 1.83.  It shows nucleolar 
localisation64. 
 
Figure 1.36 Molecular structure of a DNA-intercalating complex and its cell imaging application 
Complexes with a high lipophilicity also have a tendency to be highly cytotoxic.  The 
cytotoxicity of the complex is related to its cellular uptake efficiency if the cytotoxicity 
originates from binding to organelles.  To decrease the cytotoxicity, Lo and co-workers65 
introduced protective groups to the complex to supress non-specific interactions with the 
extracellular  matrix.  Their complexes included protective poly(ethylene glycol) (PEG) 
pendants in the ligands (Figure 1.37) which gave them a very low cytotoxicity, improved 
their water solubility and gave them a high cellular uptake efficiency. 
1.83 
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Figure 1.37  Iridium complexes with protective groups 
Iridium cyclometallates show long luminescence lifetimes, making them ideal candidates 
for time-gated experiments.  Williams and co-workers have described a pH-responsive 
probe (Figure 1.38) with a long lifetime that is dependent upon its protonation state.  It 
was used to image a cell that had also been co-stained with the nuclear-selective dye 
Hoescht 33342.  Initially the images were dominated by the Hoescht 33342, however, a 
short delay of 10 ns showed the stain to be completely excluded from the images.  Clear 
images of the iridium-derived luminescence could be observed66. 
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Figure 1.38 Molecular structure of complex and cell imaging.  Image a shows no time-gate.  Image b 
shows 10 ns delay. 
The size of metal complexes can affect their cellular uptake properties.  Lo and co-
workers synthesised a series of dendritic Ir(III) complexes67 (Figure 1.39).  Compared to 
the monomeric complexes, the dendritic complexes showed lower cellular uptake 
efficiencies.  This is due to their much larger size and higher cationic charge.  Cells loaded 
with the dentritic complexes displayed Golgi staining, as well as localization in the 
perinuclear regions. 
 
Figure 1.39 Structures of polypyridine ligands 
 
1.84 
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A recent publication has described metal complexes with a dual function as a 
luminescence pH-sensor and a pH-dependent photosensitizer.  Photosensitizers are used 
to generate 1O2 which is used as a treatment for various tumours
68.   
 
Figure 1.40 Ir Complexes 
Figure 1.40 shows Ir complexes with either NH2 or Net2 attached
68.  It was reported that 
the emission colour in aqueous solution of compound 1.89 is dependent on the pH of the 
solution69.  In neutral/basic conditions, compound 1.89 gives a red-coloured emission at 
~600 nm, but under acidic conditions (1.90) gives a green emission at ~530 nm.  Its 
electron-donating NH2 group becomes an electron-withdrawing (NH3)
+ group when 
protonated.  Conversely, the introduction of electron-donating groups results in a 
significant red shift when compared to the parent complex. 
 
1.4.5 Outlook 
Heavy-metal complexes are attractive for bioimaging purposes.  The complexes show 
good cell uptake behaviour, allowing them to be tracked using luminescence microscopy.  
They have highly tuneable physiochemical properties, resulting from easy 
functionalization of the ligands and the choice of metal ion. Their use as bioimaging 
probes is still a very new area of research but is starting to attract more attention. 
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1.5 Organometallic Complexes and Organic Light Emitting Diodes 
Organic light emitting diodes (OLEDs) are emerging as the leading technology for the new 
generation of flat screen display technologies.  They have a major advantage over LCDs 
in that no backlighting is required, which makes them thinner, lighter and more efficient.  
To enable this technology, highly efficient red (~650-700 nm), green (~500-550 nm) and 
blue (~450-470 nm) emitting compounds are required.  OLEDs generate light by 
electroluminescence (EL) from excited-state organic molecules.  They consist of a 
multilayered arrangement of thin organic films sandwiched between two electrodes.  
There are three layers: the electron-transporting layer (ETL), emitting layer (EML) and a 
hole-transporting layer (HTL).  Usually, indium tin-oxide (ITO) is used as the anode and a 
low work function metal alloy (e.g. Mg, Al, Ca) is used as the cathode.  Electrons are 
injected from the cathode and holes are injected from the anode.  The two carriers 
approach each other in the emitting layer of the OLED (Figure 1.4170).   Excited states 
may be formed if both charges arrive on a single molecule or a pair of closely spaced 
molecules.  Their radiative decay produces electroluminescence light (EL).  Hence the 
importance in optimising the luminescent properties of metal complexes70.  
 
Figure 1.41 Three-layer OLED and the radiative modes generated within the device structure 
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Platinum(II) and iridium(III) are the metals most studied in this field as they have high spin-
orbit coupling constants but can form discrete, kinetically inert, charge-neutral 
coordination complexes with aromatic ligands.  Studies have shown that through ligand 
design the excited state energies and, therefore, colour can be controlled71.  Colour tuning 
is important as the manufacture of a full colour display requires the use of emitters with all 
three primary colours29.  There is also a great demand that they give a bright colour, such 
as orange-red or light blue, for multiple colour display purposes11. 
 
When red phosphorescent materials are used in OLEDs, then triplet-triplet annihilation 
almost always occurs.  A way to avoid this is by using a host-guest doped emitter system.  
Doped OLEDs are more difficult to adapt to practical applications than non-doped OLEDs.  
It is, therefore, desirable to design non-doped compounds with high brightness and 
efficiency72. 
 
There is still a lot more work to be done to make OLED’s a commercial reality.  There are 
many challenges to overcome, such as developing a synthesis that can be used for low-
cost manufacturing. 
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dinuclear platinum(II) complexes 
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pyrazine-based ligands   
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2 Highly luminescent dinuclear platinum(II) complexes incorporating bis-
cyclometallating pyrazine-based ligands 
The aim of this part of the project was to look at the role of the bridging ligand in 
determining the photophysical properties of diplatinum(II) complexes. In order to achieve 
this goal, a series of mono and dinuclear platinum(II) complexes incorporating a variety of 
ligands have been prepared and their photophysical properties investigated. 
2.1 Synthesis 
The complexes consist of a potentially bridging cyclometallating ligand coordinated to one 
or two Pt(II) atoms.  The metals are coordinated to the same heterocycle (diazine) to give 
a rigid structure.  1,3-Diketonates are used as auxiliary ligands to give an overall neutral 
molecule.  The synthesis of these complexes is similar to one reported for monometallic 
complexes of phenylpyridine8,73. In the first step, a dichloro-bridged derivative is prepared 
by reacting the ligand with potassium tetrachloroplatinate. In all cases these dichloro-
bridged derivatives are highly insoluble compounds and were not characterised. In the 
second step the auxiliary ligand is introduced.   
 
Figure 2.1 Structures of the proligands and corresponding mono- and di-nuclear platinum(II) 
complexes  
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Attempts to synthesise the series using acetylacetonate (acac) as the auxiliary ligand 
were initially investigated (Figure 2.1), but problems with solubility meant that synthesis of 
the whole series, particularly with 2.5 and 2.6, and also of the di-nuclear complexes was 
difficult.  Of the di-nuclear complexes, only 2.12 and 2.13 were successfully synthesised 
but 2.12 was very insoluble.  Given the difficulties, a switch was made to 
dipivaloylmethane (dpm).  Dpm allows the complexes to retain good solubility without the 
need for tert-butyl groups in the cyclometallating ligands. Figure 2.2 shows the series of 
Pt(II) complexes successfully synthesised using dpm as the auxiliary ligand.   
 
 
Figure 2.2 Structures of the mono-nuclear platinum(II) complexes and dinuclear platinum(II) 
complexes 
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2.1.1 Proligand Synthesis 
Pro-ligand 2.1 is derived from 4,6-diphenylpyrimidine.  It was used in order to provide a 
comparison to work published previously43, which reports on the synthesis of mono- and 
di-Pt(II) complexes containing tert-butyl groups on the phenyl moieties of the ligand.  The 
remaining ligands (2.2-2.6) are derived from a diphenylpyrazine core.  They are all 
cyclometallated either once or twice.  The compounds based on 2.1, 2.2 and 2.3 are all 
isomers of each other so comparisons can be made on the influence of changing from 
pyrimidine to pyrazine (2.1 to 2.2 or 2.3) and also of changes in the position of the 
substituents in the pyrazine ring.  In 2.2 the phenyl rings are at the 2,5 positions and in 2.3 
at the 2,3 positions.  Increased conjugation can be investigated through 2.3-2.6 as 
additional C-C bonds are introduced and the pyrazine is replaced by quinoxaline. 
 
2,3-Diphenylpyrazine (2.3) and 2,3-diphenylquinoxaline (2.5) are commercially available, 
and so were not synthesised.  2.1 and 2.2 (Scheme 2.1) were synthesised by Suzuki 
coupling using commercially available 4,6-dichloropyrimidine or 2,5-dibromopyrazine 
(2.26) and phenylboronic acid (2.27). The reactions were carried out by stirring at 95°C 
the deairated mixture of 1 equivalent of 4,6-dichloropyrimidine or 2,5-dibromopyrazine, 2.6 
equivalents of phenylboronic acid, 5 equivalents of 2M aqueous K2CO3, 6 mol% of 
tetrakis(triphenylphosphine) palladium(0) as a catalyst, and 1,4-dioxane as a solvent.   
 
Scheme 2.1 Synthesis of 2.2 using the Suzuki cross-coupling reaction 
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2.4 (Scheme 2.2) and 2.6 were synthesised by following literature procedures74,75.  
Conditions for the condensation reactions included refluxing 1 equivalent of 9,10-
phenanthenequinone (2.28) and ethylenediamine (2.29) (1.3 eq.) or o-phenylenediamine 
(1 eq.) in ethanol, followed by the addition of an acid and further reflux under nitrogen. 
 
Scheme 2.2 Synthesis of 2.4 by a condensation reaction 
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2.1.2 Platinum(II) Complex Synthesis 
The monometallic Pt(II) complexes with acac as the auxiliary ligand (2.7-2.11), were 
obtained by heating at reflux a mixture of the proligand and one equivalent of K2PtCl4 in 
acetic acid for up to 2 days.  The resulting dichloro-bridged intermediates were then 
reacted with sodium acetylacetonate to give, after purification by column chromatography, 
the mono-platinum complexes.  The synthesis of complex 2.9 is given in Scheme 2.3. 
 
 
Scheme 2.3 Synthesis of complex 2.9 
The monometallic Pt(II) complexes with dpm as the auxiliary ligand, were obtained by 
heating at reflux a mixture of the proligand and one equivalent of K2PtCl4 in acetic acid for 
up to 3 days.  The resulting dichloro-bridged intermediates were then reacted with 
dipivaloylmethane in the presence of base to give, after purification by column 
chromatography, the mono-platinum complexes in a low to moderate yield.  The formation 
of a small amount of the corresponding di-platinum complex was also observed in each 
case.  The synthesis of complex 2.15 is shown in Scheme 2.4. 
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Scheme 2.4 Synthesis of complex 2.15 
The dinuclear platinum(II) complexes were synthesised either by reaction of the mono-Pt 
complex with one equivalent of K2PtCl4 or by reacting the proligand with two equivalents 
of K2PtCl4.  Under these conditions, it was found that, although the dinuclear complex was 
the main product, the corresponding mono-platinum complex was still present in the 
mixture.  In general, it was more convenient to prepare the two complexes together in a 
‘one pot’ synthesis by reaction of 1 equivalent of the proligand with 2 equivalents of 
K2PtCl4 (Scheme 2.5).  
 
Scheme 2.5 One pot synthesis of 2.15 and 2.21 
 
After introduction of the dpm ancillary ligand under conventional conditions, the mono- 
and dinuclear platinum complexes are readily separated by column chromatography 
(typically on silica gel eluting with dichloromethane) to give both products in one 
procedure. 
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2.1.2.1 Yields 
The yields of the platinum complexes are low.  For the mono-Pt dpm complexes, yields 
were found to be ~15-45% and the di-Pt dpm complexes yields at ~1-33%.  An alternative 
synthesis was tried using 2.1 with acac as the auxiliary ligand.  The phase transfer 
synthesis was carried out by adding potassium tetrachloroplatinate to a solution of 
tetrabutylammonium bromide (2.31) in DCM.  This was added to a solution of 2.1 in 
ethoxyethanol and heated at 100oC.  The solution was purged with nitrogen to remove the 
DCM and then left stirring overnight.  The precipitate was then filtered off and treated with 
acac in the usual way to give 2.7 (Scheme 2.6). 
 
Scheme 2.6 Synthesis of 2.7 by phase transfer 
Complex 2.7 has also been synthesised in the usual way with acac as the auxiliary ligand.  
The yield was 26%.  Using the alternative phase transfer method gave a lower yield of 
11%, so was not investigated further.  It is unclear as to the reason why the yields are so 
poor.  However, the first stage of the synthesis gives a yield of 90% for the dimer (or 43% 
using the alternative synthesis) so it seems that a lot of material is lost whilst attaching the 
auxiliary ligand. 
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2.1.2.2 Alternative synthesis 
As mentioned previously, initial attempts at synthesis of the compounds were made using 
acac as the auxiliary ligand.  This proved difficult as the products turned out to be black 
insoluble compounds, making purification very difficult.  Several attempts were made to 
synthesise the di-Pt complexes with acac but with no success.  Firstly, a change of 
solvent from acetone to ethoxyethanol was made in order to be able to raise the reaction 
temperature; this resulted in the same black insoluble compound.  Purification by column 
chromatography only recovered the starting material, when either the ligand had been 
reacted with 2 equivalents of platinum or when the mono-Pt complex reacted with 1 
equivalent of platinum, and a lot of the black material was left stuck on the column.  
Attempts were also made to break the di-Cl bridged complex by refluxing in 
dimethylsulfoxide before then going on to add the acac to the complex.  This method of 
synthesis has been used successfully43 for 2.1.  However, through the 1H-NMR spectra of 
the crude product it did look as if a mixture of mono-Pt and di-Pt complexes were present.   
The Di-Pt complex was too insoluble to be purified.  Once again, purification by column 
chromatography just recovered the mono-Pt complex.  A switch in the acac salt was also 
made from sodium acetylacetonate to lithium acetylacetonate (purchased from Sigma 
Aldrich).  A synthesis was carried out to make complex 2.7 as this had already been 
successfully synthesised using Na (acac) and so the same conditions were followed.  The 
results were very poor with a very messy 1H-NMR spectrum. Further purification would 
have been needed to try to recover the product which was not needed when using Na 
(acac).  It was decided not to pursue this route any further as it was then thought that 
using dpm would be a better option to improve on the solubility of the complexes. 
 
 A recent paper73 describes a one-pot synthesis of cyclometallated platinum(II) β-
diketonates carried out at ambient temperature.  The starting material [PtMe2(SMe2)]2 was 
stirred at room temperature in THF along with 2 equivalents of the proligand (2.33) for 1 
hour.  CF3SO3H was then added followed by 2 equivalents of Na acac and left stirring at 
room temp for 1.5 hours to give the pure product (2.34) in 87% yield (Scheme 2.773).   
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Scheme 2.7 One pot, room temperature synthesis of cyclometallated Pt(II) β-diketonates 
The one-pot synthesis was first attempted with 2.3 using the same conditions as shown in 
Scheme 2.7 but using TFA rather than CF3SO3H.  The 
1H-NMR spectrum of the crude 
product, showed that the reaction had not gone to completion.  More acac was added 
along with K2CO3 and acetone and the mixture was refluxed for 4 hours.  This time the 
1H-
NMR spectrum showed that the reaction had gone to completion and that there was a 
mixture of mono- and di-Pt complexes.  Similar reactions were attempted with ligands 2.1 
and 2.4 – 2.6, but again these were unsuccessful at room temperature.  Most of these 
reactions gave an oily black solid that was insoluble in DCM and so could not be purified. 
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2.2 The role of the auxiliary ligand 
As mentioned previously, initial, attempts at synthesising the series of complexes were 
made using acac as the auxiliary ligand.  Problems with solubility led us to a switch to 
using dpm.  The introduction of the tert-butyl groups gave a much improved solubility and, 
hence, the complete series could be synthesised.   
 
It has been reported that in general, the auxiliary ligand does not significantly affect the 
photophysical properties of a complex [Pt(C^N)(X^Y)]76,6.  In order to check that the same 
could be said of these complexes, the UV spectra were compared using 2.3.  Both the 
acac and dpm complexes have been synthesised using 2.3 (Scheme 2.8). 
 
Scheme 2.8 2,3-diphenylpyrazine(2.3) and its mono- and di-Pt derivatives with acac and dpm auxiliary 
ligand 
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Chart 2.1 shows the UV-vis absorption spectra for 2.9 and 2.16. Both complexes absorb 
at a very similar wavelength (392 nm for acac and 398 nm for dpm).  Chart 2.2 also shows 
very little difference in absorption for the di-Pt complexes.  2.22 is slightly more red-shifted 
than 2.13 (443 nm for acac and 450 nm for dpm).  The solubility of the complex is 
certainly improved for the DPM auxiliary ligand. 
 
Chart 2.1 UV spectra for mono-Pt 
 
 
Chart 2.2 UV spectra for di-Pt 
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2.3 Absorption Spectroscopy 
2.3.1 Acetylacetone (acac) 
Complexes 2.1, 2.2, 2.3, 2.4 and 2.6 were synthesised as mono-Pt complexes with acac 
co-ligands, and their absorption data is shown in Table 2.1 and the spectra shown in 
Chart 2.3.  Also 2.12 and 2.13 were synthesised but 2.12 was too insoluble to get UV 
measurements.  Chart 2.4 shows the spectra comparing the mono- and di-platinum 
complexes for 2.3 with acac as the auxiliary ligand.  Comparisons can be made with the 
complexes of dpm as the auxiliary ligand (see Table 2.2 later in this chapter) and the 
wavelengths are very similar for both acac and dpm.  
Table 2.1 UV-visible absorption data for the complexes with acac as the auxiliary ligand 
Complex max / nm  ( / M
–1cm–1) 
2.7 301 (8476), 337 (8785), 392 (4490) 
2.8 336 (11370), 359 (9615), 393 (4014), 434 (3364) 
2.9 337 (8785), 392 (4490), 440 (1808) 
2.13 317 (22833), 390 (23414), 443 (17114), 573 (565) 
2.10 340 (9152), 402 (5848), 459 (1625) 
2.11 280 (41231), 400 (11431), 454 (8062), 510 (4971) 
 
The absorptions are progressively more red-shifted through the series of ligands, with 
2.11 being the most red-shifted.  The formation of the C-C bond is likely to give a planar 
structure for 2.10 but not for 2.9.  Also there could be some steric crowding of C-H bonds 
within 2.9, meaning  less of a red-shift than 2.10. 
57 
 
 
Chart 2.3 UV data for complexes 2.7, 2.8, 2.9, 2.10 and 2.11 
As mentioned previously, the only di-Pt complex with an acac co-ligand to be successfully 
synthesised and characterised by UV was 2.13.  Chart 2.4 shows the UV data for both 2.9 
and 2.13.  The di-Pt complex (573 nm) is much more red shifted compared to the mono-Pt 
complex (440 nm).  Returning to the mono-Pt complexes, 2.11 has a much higher 
extinction coefficient compared to the others and is also the most red-shifted.  This is also 
true of the dpm complexes which will be discussed later on in this chapter.  Both the acac 
and the dpm complexes gave very similar UV results with 2.9 giving an absorption at 449 
nm and 2.13 giving an absorption at 572 nm.  
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Chart 2.4 UV data for complexes 2.9 and 2.13  
 
2.3.2 Dipivaloylmethane (dpm) 
The absorption data for all 12 dpm complexes are compiled in Table 2.2, and spectra are 
shown in Chart 2.5 and Chart 2.6.  The measurements for the dpm complexes were 
carried out by Dr J.A.G. Williams of Durham University.  The mononuclear complexes 
display absorption spectra that are quite typical of platinum(II) complexes with N^C-
cyclometallating, aryl-heterocyclic ligands, such as Pt(ppy)(acac) and related derivatives. 
There are intense bands in the UV region, < 350 nm, with extinction coefficients  in the 
range 10 000 – 30 000 M–1cm–1, corresponding to 1–* transitions associated with the 
ligands.  Somewhat weaker bands,  < 10 000 M–1cm–1, in the visible region (390 – 500 
nm) have no counterparts in the spectra of the free proligands.  Based on the conclusions 
of previous studies8,77,78,79, and on the results of time-dependent density functional theory 
calculations for the dpm series of complexes(discussed later in this chapter), at least 
some of these bands can be attributed to charge-transfer transitions from the aryl–metal 
unit to the heterocyclic ring, reflecting the predominant localisation of the frontier orbitals 
on these two different parts of the molecule. 
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The dinuclear complexes 2.20, 2.21 and 2.22 display very different spectra from their 
corresponding mononuclear analogues 2.14, 2.15 and 2.16.  For the complexes of 2.1 
and 2.2, the set of lower energy bands in the visible region are substantially red-shifted in 
the dinuclear compared to the mononuclear complexes (lowest-energy band shifts by 
around 4000 cm–1), and there is a large increase in the extinction coefficients of most of 
the bands.  The visible-region bands in 2.22, on the other hand, are scarcely shifted 
compared to 2.16, although there is again a very large increase in the extinction 
coefficients.  The red-shift in the complexes of 2.20 and 2.21 is likely to be associated with 
the extension of conjugation that would be expected to accompany the introduction of the 
second metal ion.  In the case of 2.22, on the other hand, it seems likely that steric 
crowding of the C–H bonds of the pendent phenyl groups is occurring, which would 
account for the lack of red shift. 
 
Chart 2.5 UV-visible absorption spectra of 2.14, 2.15 and 2.16 (blue, red, and black solid lines 
respectively) and of 2.20, 2.21 and 2.22 (blue, red, and black short-dashed lines respectively) in CH2Cl2 
solution at 298 K.  The low-energy region of the spectra of 2.21 and 2.22 is shown on an arbitrarily 
expanded scale (red and black long-dashed lines respectively). 
The absorption spectra of all the other complexes (2.17, 2.18, 2.19, 2.23, 2.24 and 2.25) 
are shown in Chart 2.6, together with those of 2.16 and 2.22 again as a point of 
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comparison.  Considering first the mononuclear complexes, it can be seen that all four 
display spectra that are quite similar to one another in form, but the visible-region bands 
move progressively further to the red.  The displacement is small on going from 2.16 to 
2.17 (~700 cm–1), but nevertheless the trend would be consistent with the planarization of 
the structure that becomes possible upon fusing the aromatic rings and loss of the 
sterically unfavourable interaction between the C–H bonds on the two rings mentioned 
above.  A much larger red-shift accompanies the change from the pyrazine unit of 2.16 to 
the quinoxaline of 2.18 (around 1800 cm–1 for the lowest-energy band, and around 2600 
cm–1 for the next lowest).  Again, it is clear that the introduction of the second metal ion 
leads to a red-shift in the visible region bands, and to a large increase in the molar 
absorptivity of these bands. 
 
 
Chart 2.6 UV-visible absorption spectra of 2.16, 2.17, 2.18 and 2.19 (black, blue, green, and red solid 
lines respectively) and of 2.23, 2.24 and 2.25 (correspondingly coloured dashed lines) in CH2Cl2 
solution at 298 K. 
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Table 2.2 UV-visible absorption data for the complexes with dpm as the auxiliary ligand 
Complex max / nm  ( / M
–1cm–1) 
2.14 256 (25200), 301 (31600), 338sh (10600), 408 (9550) 
 
2.20 257 (47000), 326 (63200), 430 (17100), 481 (24300), 
532sh (1990) 
2.15 254 (26800), 299 (25400), 342 (17300), 398 (6430), 435 
(5240) 
2.21 253 (35300), 296 (26500), 333 (21900), 372 (16600), 453 
(15900), 503 (6830), 618 (346) 
2.16 252 (23800), 292 (16900), 340 (11900), 398 (6170), 449 
(2170) 
2.22 245 (36700), 301 (20300), 319 (20700), 390 (19600), 451 
(15200), 572 (310) 
2.17 251 (66000), 278 (42100), 344 (18900), 407 (11800), 463 
(3190) 
2.23 258 (59300), 295 (25900), 308 (25700), 350 (25800), 428 
(10100), 462 (19400), 509 (11500) 
2.18 252 (40000), 294 (20000), 373sh (9380), 388 (10600), 
445 (6470), 488sh (3790) 
2.24 251 (42000), 313 (21600), 387 (14200), 428 (8610), 496 
(1360) 
2.19 251 (52300), 282 (38000), 383sh (7870), 401 (10300), 
463 (7790), 511 (4520) 
2.25 266 (29000), 301sh (13600), 324sh (11500), 396 (3070), 
422 (3890), 476sh (3350), 519 (7780), 569 (6690) 
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2.4 Photoluminescent Properties 
All twelve dpm complexes are luminescent in degassed solution at room temperature, 
most of them intensely so.  The emission data for the compounds are compiled in Table 
2.3, and the spectra are shown in Chart 2.7 and Chart 2.8.  The trends in emission 
maxima are mostly quite similar to those observed in the absorption spectra.  In particular, 
it may be immediately seen that, for a given ligand, the spectrum of the binuclear complex 
is significantly red-shifted compared to that of the corresponding mononuclear complex.  
The shift is in the range 1600 – 1900 cm–1 for the five pairs of pyrazine-based complexes 
(based on the emission maxima), and 1270 cm–1 for the pyrimidine pair (2.14 and 2.20). 
 
Amongst the three isomeric complexes 2.14 – 2.16, the pyrimidine complex 2.14 emits at 
a higher energy (max = 520 mm), while the two pyrazine complexes emit in a similar 
region to one another, with 2.15 displaying a more structured profile.  Meanwhile, the 
trend amongst the four complexes 2.16 – 2.19 is similar to that in absorption, except that 
2.18 emits at marginally lower energy than 2.19 – the opposite of the trend in absorption – 
and its spectrum is markedly broader. 
 
Two instances of a reversal in the relative order of emission energies versus absorption 
energies are observed amongst the binuclear complexes.  Thus, 2.22 emits at significantly 
lower energy than 2.20, contrary to the absorption being significantly lower in energy for 
the latter.  The second instance is the pair of complexes 2.24 and 2.25, where the 
emission of the former has a slightly longer max, despite having an absorption maximum 
at a higher energy.  Excited-state reorganisation at room temperature can be anticipated 
for 2.24 similar to that proposed for 2.22, given the expected sterically unfavourable 
interactions in the ground state.  At 77 K, the emission spectra show otherwise similar 
trends as at room temperature but the spectra become more vibrationally resolved.  The 
observed vibrational spacing is around 1200 – 1400 cm–1, as typically expected for 
coupling to aromatic ring vibrations. 
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Table 2.3 Emission data for the dpm complexes in degassed CH2Cl2 at 298 K except where stated otherwise 
Complex max / nm lum 
(a)  / ns (b)  
 
kQ
SQ  (c) 
/ 10
7
 M
–1
s
–1
 
kr 
(d) 
/ 104 s–1 
 knr 
(d) 
/ 104 s–1 
kQ 
O2 (e) 
/ 108 M–1s–1 
EA–E (f) 
/ cm–1 
Emission at 77 K (g) 
max / nm  / s 
2.14 521 0.25 1600 [460] 87 16 47 7.0 5320 501, 527, 573sh 6.4 
2.20 558, 594 0.36 1100 [670] (h) 33 58 2.6 2870 539, 582, 630 4.3 
2.15 565, 608 0.30 8900 [840] 71 3.4 7.9 4.9 5290 554, 603, 654 11 
2.21 628, 685, 753 0.41 3200 [680] (h) 13 18 5.3 3960 617, 676, 742 3.4 
2.16 554, 578 0.43 7700 [850] 210 5.6 7.4 4.8 4220 536, 576, 618 11 
2.22 612 0.37 4000 [750] 3.5 9.3 16 4.9 5830 586, 634, 693 6.1 
2.17 568 0.15 2600 [510] 270 5.8 33 7.2 3990 528, 566, 615 11 
2.23 628 0.20 1800 [650] 27 11 44 4.5 3720 601, 654, 716 7.0 
2.18 668 0.14 3700 [700] 15 3.8 23 5.3 5520 625, 677, 747sh 5.7 
2.24 749 0.025(i) 910 [490] (h) 2.7(i) 110 4.3 6810 694, 760 3.5 
2.19 639, 686 0.13 3800 [700] 180 3.4 23 5.3 3920 617, 676, 746 1.3 
2.25 728, 799 0.027(i) 2000 [580] (h) 1.4(i) 49 5.6 3840 712, 793 1.5 
(a) Measured using [Ru(bpy)3]Cl2 as the standard.  (b) Values in air-equilibrated solution in parenthesis.  (c) Self-quenching rate constant, estimated from a plot of 
–1
 versus concentration.  (d) kr and knr are the radiative and non-radiative decay rate constants, estimated from the 
quantum yield and lifetime assuming that the emissive state is formed with unitary efficiency.  (e) Bimolecular rate constant for quenching by O2, estimated from the luminescence lifetimes in degassed and air-equilibrated solutions, and taking [O2] = 2.2 mM in CH2Cl2 at p = 1 atm air 
and T = 298 K.  (f) The difference between the energy of the lowest-energy (singlet) absorption band and the emission band, using the max values.  (g) In diethyl ether / isopentane / ethanol (2:2:1 v/v).  (h) The change in lifetime with concentration was too small to estimate a self-
quenching rate constant, being scarcely larger than the uncertainty on the measurements.  (i) The quantum yields of these two complexes will be underestimated, owing to a significant part of the emission falling out of the range of detection of our equipment.  Radiative rate constants 
will be underestimated as a result. 
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Chart 2.7  Top: Normalized emission spectra of 2.14 – 2.16 (blue, red, and black solid lines 
respectively, legend as in Figure 2) and of 2.20 – 2.22 (blue, red, and black short-dashed lines 
respectively) in CH2Cl2 solution at 298 K.  Bottom: Corresponding spectra in an EPA glass at 77 K 
(EPA = diethyl ether / isopentane / ethanol, 2:2:1 v/v). 
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Chart 2.8 Top: Normalized emission spectra of 2.16 – 2.19 (black, blue, green, and red solid lines 
respectively) and of 2.22 – 2.25 (correspondingly coloured dashed lines) in CH2Cl2 solution at 298 K.  
Bottom: Corresponding spectra in an EPA glass at 77 K. 
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The photoluminescence quantum yields, lum, are high for many of the complexes (Table 
2.3), falling off to < 0.1 only for the most red-emitting complexes, where much of the 
emission lies in the near infra-red.  Binuclear complexes such as 2.21 and 2.22 are 
particularly striking in that they have quantum yields of around 0.40 at a max that matches 
well with those of the standard red emitters in RGB displays (e.g. Eu3+ phosphors emit at 
around 617 nm).  Indeed, these complexes are brighter than many of the widely-
investigated iridium(III) complexes of phenylisoquinoline and benzothienylpyridine 
ligands80,18,81, which emit in a similar region, and are competitive with quinoxaline-based 
iridium(III) complexes11,14. 
  
The luminescence lifetimes are of the order of a few microseconds in degassed solution 
and, for each pair, the lifetime of the binuclear complex is shorter than that of its 
mononuclear analogue.  By estimating the radiative, kr, and non-radiative, knr, decay rate 
constants from the quantum yield and lifetime data (Table 2.3), it can be seen that the 
introduction of the second metal ion facilitates the radiative decay process by a factor of 
around 2.  Apparently, the emissive transition becomes more allowed in the binuclear 
complex.  Whilst it might be tempting to attribute this effect to additional spin-orbit coupling 
associated with the second heavy metal ion, it should be noted that the molar 
absorptivities of the lowest-energy spin-allowed absorption bands are also increased by 
around two-fold in the binuclear complexes compared to their mononuclear analogues 
(Table 2.2). 
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2.5 Time-dependent density functional theory (TD-DFT) calculations 
Density functional theory calculations have been carried out by Dr Marcus Durrant on all 
of the compounds shown in Figure 2.2.  In order to facilitate the calculations, acac was 
used rather than dpm.  As discussed in the previous section, changing from dpm to acac 
has very little influence on the photophysical properties of these complexes.   All 
calculations were performed with Gaussian09W, using the B3LYP functional82 and 6-
31+G(d) basis set for all atoms except Pt, for which the LanL2DZ basis set was 
employed83.  After full geometry optimization, the visible spectra were calculated by TD-
DFT, both in vacuum and in dichloromethane solution using the polarized continuum 
model for the solvent84. 
In addition to the spectroscopic analysis, the DFT calculations provide a measure of the 
relative ground-state stabilities of the mononuclear and dinuclear complexes of a given 
ligand.  For each ligand, the energy changes have been calculated for the hypothetical 
reactions [1] and [2], generating both the mono and dinuclear complexes (Ln denotes the 
proligands): 
 
LnH2  +  Pt(acac)2  →  Pt(acac)LnH  +  acacH                                      [1] 
Pt(acac)LnH  +  Pt(acac)2  →  {Pt(acac)}2Ln  +  acacH                        [2] 
 
The energy changes (E) associated with these reactions are shown in Table 2.4.   
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Table 2.4 Calculated gas-phase energy changes for reactions [1] and [2] generating the mono or 
dinuclear complex.
 
Species Ln 
n = 
Reaction [1] 
→ Pt(acac)LnH 
∆E / kJ mol–1 
Reaction [2] 
→{Pt(acac)}2Ln 
∆E / kJ mol–1 
 
2.1 – 13.4 – 42.0 
2.2 – 10.3 – 46.7 
2.3 – 4.2 – 32.8 
2.4 – 6.5 – 33.0 
2.5 + 25.8 – 12.4 
2.6 + 14.9 – 23.6 
 
As the data shows, the introduction of the second Pt center is always energetically more 
favourable than the first, indicating a synergy in the binding.  The stabilities of the 
complexes can be linked to steric effects.  The least sterically hindered ligands 2.1 and 
2.2 give the most stable complexes, whilst 2.5 and 2.6 are the least stable.  Their 
instability could be explained by the close contacts between the O atoms of the acac 
ligands and the CH groups of the extra ring (Figure 2.3). The closest CH---O contacts are 
2.68Å for 2.24 and 2.37Å for 2.25 (Table 2.5).  The fused ring systems 2.4 and 2.6 are a 
little better than their ortho-diphenyl analogues 2.3 and 2.5 respectively in terms of 
stability. 
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Table 2.5 Closest contact between the O atom of the acac ligand and the CH group of the ring 
Species Pt2Ln(acac)   n = Closest CH---O contact (Å) 
2.1 3.88 
2.2 3.86 
2.3 3.52 
2.4 3.71 
2.5 2.68 
2.6 2.37 
 
 
Figure 2.3 Calculated structure of 2.24, showing the steric distortion centred on the pyrazine ring.  The 
dotted lines show the close contacts between the C–H groups and O atoms. 
As expected, the ligands whose rings are linked by rotatable C–C bonds are non-planar in 
these complexes.  In the mononuclear complexes of 2.3 and 2.5, and all the complexes of 
the other ligands, the coordinated rings are essentially co-planar; however, some 
distortion is observed for the dinuclear complexes of 2.3 and 2.5.  This is greatest for 2.24, 
as shown in Figure 2.3; the pyrazine ring is twisted, such that carbons 1 and 2 are 
displaced by 0.12 Å above and below the mean plane of the ring. 
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Figure 2.4 Frontier orbital diagrams for 2.15 (left) and 2.21 (right). 
The frontier orbitals for the mono- and dinuclear complexes of L2, which are shown in 
Figure 2.4, are representative of all six pairs of complexes.  For all 12 complexes, the 
HOMO’s are derived mainly from combinations of platinum d-orbitals with π-orbitals of the 
surrounding ligands, with only small contributions from the pyrazine and pyrimidine rings.   
These heterocyclic rings are much more important components of the LUMO’s.  The 
frontier orbitals of the dinuclear complexes are all symmetrically distributed over both 
halves of the molecules.  Frontier orbital diagrams for the remaining complexes can be 
found in the appendix. 
 
There is a good correlation between the energy of the LUMO and energy of the lowest 
energy singlet transition in the calculated spectra (the data is shown in the appendices).  
The calculated absorption spectra are shown in Chart 2.9, and are in generally good 
agreement with the experimentally measured spectra.  Calculations including the triplet 
excited states for 2.20, 2.21 and 2.22 in dichloromethane placed the formally spin-
forbidden S0→T1 transitions at 538, 622 and 591 nm respectively, in good agreement 
with the experimental phosphorescence data discussed previously. 
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Chart 2.9 Simulated UV-visible absorption spectra of the complexes obtained by TD-DFT calculations 
with a CH2Cl2 implicit solvent model.  Spectra are displaced vertically for clarity.  Spectra of 
mononuclear complexes are represented by broken lines and dinuclear complexes are represented by 
solid lines. 
 
2.6 Concluding Discussion 
It has been previously shown how 4,6-diphenylpyrimidine can be used as a bridging 
ligand to prepare dinuclear cyclometallated platinum(II) complexes43.  This study shows 
that diphenylpyrazines can likewise generate dinuclear platinum(II) complexes, through 
metallation of the two pendent phenyl rings and binding of the metal ions to the two 
nitrogen atoms of the central heterocycle.  Both the 2,3- and 2,5-substituted isomers of 
diphenylpyrazine can be employed, along with diphenylquinoxaline and derivatives in 
which the phenyl rings are interlinked through their ortho positions.  Mono- and di-nuclear 
complexes can be isolated from a single reaction by chromatographic separation.  
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The introduction of the second metal ion leads, for all six ligands investigated, to a 
significant stabilization of the LUMO of around 0.3 eV, according to TD-DFT calculations 
(data shown in appendices).  In contrast, the HOMO energy seems to be influenced rather 
little.  These contrasting effects are intuitively in line with the typical distribution of frontier 
orbitals in cyclometallated complexes of aryl-heterocycles, in that the ring to which two 
metal ions are bound is the heterocycle, on which the LUMO is predominantly localised.  
The decreased HOMO–LUMO gap that ensues leads to red-shifted absorption and 
emission spectra for the dinuclear complexes compared to their mononuclear analogues.  
Meanwhile, the increased conjugation within the heterocycle on going from a pyrazine 
through quinoxaline to a phenazine unit (as in 2.6) has a much more significant effect on 
the LUMO, leading to the progressive shift towards the red region observed in the optical 
spectra. 
 
Of particular interest is the effect of the second metal ion on the radiative rate constant kr.  
For all of the systems in which this parameter can be estimated with confidence (Table 
2.3), the value increases upon introduction of the second metal ion, despite the red shift.   
In summary, dinuclear cyclometallated complexes are shown to offer interesting potential 
for obtaining phosphorescent materials that both absorb strongly and emit brightly at 
unusually low energies.  Further derivatisation of the diarylpyrazine unit can be confidently 
expected to lead to further new compounds with opportunities for controlling excited states 
for contemporary applications, such as in imaging, solar energy conversion, and light-
emitting displays. 
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Chapter 3: The effects of the 
Substitution Pattern in Bridging 2,5-
diphenyl pyrazine ligands  
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3 The effects of the Substitution Pattern in Bridging 2,5-diphenyl 
pyrazine ligands 
The aim of this section of work is to look at the effects of the substitution pattern in 
bridging 2,5-diphenyl pyrazine ligands on the photophysical properties of their 
cyclometallated platinum(II) complexes. In order to achieve this goal a series of 
substituted 2,5-diphenylpyrazines with electron withdrawing and donating groups were 
prepared.  These proligands were then used to prepare the corresponding mono- and di-
platinum(II) complexes.  Their photophysical properties were investigated. 
 
3.1 Synthesis 
A range of ligands as well as their mono- and di-platinum (II) complexes are depicted in 
Figure 3.1 The substituents are added to the phenyl moiety of the proligand and are either 
electron donating (-OMe, -CH3, ) or electron withdrawing (-F).  An unsubstituted (H) 
derivative was prepared earlier as part of the work in chapter 2.  
 
75 
 
 
Figure 3.1 Structures of the proligands, mono-nuclear platinum(II) complexes, and dinuclear 
platinum(II) complexes 
 
3.1.1 Proligand Synthesis 
2.2 was synthesised via the Suzuki cross coupling reaction using commercially available 
2,5-dibromopyrazine (2.26) and phenylboronic acid (2.27). The reaction was carried out 
by stirring at 95°C a deairated mixture of 1 equivalent of 2,5-diphenylpyrazine, 2.6 
equivalents of phenylboronic acid, 5 equivalents of 2M aqueous K2CO3, 6 mol% of 
tetrakis(triphenylphosphine) palladium (0) as a catalyst and 1,4-dioxane as solvent. The 
isolated yield of the reaction was only 33% indicating that the reaction conditions should 
be further optimised. However, the big disadvantage of the reaction is the expensive 
starting materials, especially 2,5-dibromopyrazine. 
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Figure 3.2 Synthesis of 2. by Suzuki cross coupling reaction 
 
For this reason, an alternative route to 2,5-diphenylpyrazines based on the formation of 
the central pyrazine ring was then tested85,86.  Commercially available and cheap 
acetophenones were brominated in diethyl ether and then treated with ammonia in 
ethanol.  
 
Scheme 3.1 General synthesis of the proligands using substituted acetophenones 
 
Scheme 3.1 shows the general mechanism of the reaction. The bromoacetophenones 
(3.11) react with ammonia to give the corresponding aminoacetophenones (3.12). The 
latter spontaneously dimerise to form dihydropyrazines, which exist in two tautomeric 
forms (3.13, 3.14). If left stirring at room temperature, the dihydropyrazines are oxidised 
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by air to give pyrazines (3.15).  The oxidation is, however, quite a slow process.  In order 
to facilitate it, hydrogen peroxide was added leading to the targeted pyrazines. If oxidation 
was not complete, the crude product was redissolved in ethanol and more hydrogen 
peroxide was added.  Figure 3.3 shows the NMR of the proligand 3.1 not quite at 
completion, as there are also peaks for the dihydropyrazine.  After further oxidation 
overnight, Figure 3.4 shows that the reaction has gone to completion.  
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Figure 3.3 
1
H-NMR image showing the presence of dihydropyrazines 
a b u n d a n c e
0
1 . 0
2 . 0
3 . 0
4 . 0
5 . 0
6 . 0
X  :  p a r t s  p e r  M i l l i o n  :  P r o t o n
9 . 0 8 . 0 7 . 0 6 . 0 5 . 0 4 . 0 3 . 0 2 . 0 1 . 0 0
   9 . 0 3 0   9 . 0 1 8   9 . 0 0 7   8 . 8 9 6    8 . 2 9 7   8 . 2 7 6   8 . 0 4 8   8 . 0 2 8   7 . 9 5 3   7 . 9 3 2   7 . 3 3 2   7 . 3 1 2   7 . 2 4 7   6 . 9 8 3   6 . 9 3 0    4 . 7 4 2    4 . 2 0 2   4 . 1 8 8    2 . 5 8 1   2 . 5 7 0   2 . 4 7 9   2 . 4 5 7   2 . 4 2 4   2 . 4 0 3   2 . 3 8 7   2 . 3 7 0   2 . 2 6 3    1 . 6 1 6   1 . 2 4 9   1 . 2 3 0   1 . 2 1 3    0 . 1 3 2   0 . 0 4 3
  - 0 . 0 0 7  - 0 . 0 1 5  - 0 . 0 2 3  - 0 . 0 3 2
9 . 8 1
4 . 6 1
3 . 8 1
2 . 0 0
1 . 0 0
0 . 5 0
0 . 3 5
1 
B 
2,5 
3,4 
A 
79 
 
 
Figure 3.4 
1
H-NMR image showing the pure product after further oxidisation 
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This method of first bromination of acetophenones followed by treatment with aqueous 
ammonia has advantages over the Suzuki cross-coupling as the costs are lower and the 
reaction can be easily scaled up.  We therefore used this method of synthesis to prepare 
the whole series of compounds.  
 
3.1.2 Platinum(II) complex synthesis 
The mono and dimetallic Platinum(II) complexes, were obtained by refluxing the ligand 
with 1.5 equivalents of K2PtCl4 in acetic acid for 1 day.  The intermediate is then refluxed 
with 2 equivalents of DPM and 3 equivalents of potassium carbonate in acetone for 1 day.  
The mono- and dinuclear platinum complexes are readily separated by column 
chromatography (typically on silica gel eluting with dichloromethane) to give both products 
in one procedure (Scheme 3.2).  Yields were 6-35% for monometallic complexes and 1-
15% for dimetallic complexes. 
3.1.2.1 Complexes 2.15 And 2.21 
 
Scheme 3.2 One pot synthesis of 2.15 and 2.21 
 
Scheme 3.2 shows the one pot synthesis of 2.15 and 2.21.  A yield of 35% for mono-Pt 
and 15% for di-Pt was achieved.  Figure 3.5 shows the 1H-NMR spectra of 2.2 (bottom 
spectrum), 2.15 (middle spectrum) and 2.21 (top spectrum).   
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It can be seen that the reaction has worked as signals for protons have shifted compared 
to the starting proligand and one proton disappears due to the formation of the C-Pt bond.  
Of the mono-Pt complex, protons 1 and 6 can be assigned by the Pt satellites (just seen 
on Figure 3.5).  Proton 6 has satellites (3JH-Pt 45.8 Hz) due to the close proximity to 
platinum whereas proton 1 does not.  The difference between the mono-Pt and di-Pt 
complexes are also apparent as the di-Pt complex has equivalent protons from both 
phenyl moieties of the ligand, whereas the mono-Pt complex protons are not equivalent, 
the protons on both phenyl moieties are in different environments due to the presence of 
the platinum attached to one of them.  
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Figure 3.5 Expanded area of the 
1
H-NMR spectra of 2.21 (bottom spectrum), 2.15 (middle spectrum) and 2.2 (top spectrum) 
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3.1.2.2 Complexes 3.4 and 3.7 
 
Scheme 3.3 One pot synthesis of 3.4 and 3.7 
 
Scheme 3.3 shows the one pot synthesis of 3.4 and 3.7.  A yield of 6% for mono-Pt and 
1% for di-Pt was achieved.  Figure 3.6 shows the 1H-NMR spectra of 3.7 (bottom 
spectrum), 3.4 (middle spectrum) and 3.1 (top spectrum).  The complex is derived 
analogously to 2.2 and so the same conclusions can be drawn as to interpreting the 1H-
NMR.  Proton 5 of Figure 3.6 has platinum satellites (3JH-Pt 34.8 Hz) and so can easily be 
assigned.  In addition, there are also two singlets of integral three for the methyl groups 
attached to the pyridyl moiety on the mono-Pt spectrum.  The di-Pt spectrum shows it as 
one singlet of integral six. 
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Figure 3.6 Expanded area of the 
1
H-NMR spectra of 3.7 (bottom spectrum), 3.4 (middle spectrum) and 3.1 (top spectrum) 
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3.1.2.3 Complexes 3.5 and 3.8 
 
Scheme 3.4 One pot synthesis of 3.5 and 3.8 
Scheme 3.4 shows the one pot synthesis of 3.5 and 3.8.  A yield of 35% for mono-Pt and 
3% for di-Pt was achieved.  Figure 3.7 shows the 1H-NMR spectra of 3.8 (bottom 
spectrum), 3.5 (middle spectrum) and 3.2 (top spectrum).  The complex is derived 
analogously to 2.2 and so the same conclusions can be drawn as to interpreting the 1H-
NMR.  Proton 5 of Figure 3.7 has platinum satellites (3JH-Pt 43.1 Hz) and so can easily be 
assigned.  In addition, there are also two singlets of integral one for the methoxy groups 
attached to the pyridyl moiety on the mono-Pt spectrum.  The di-Pt spectrum shows it as 
one singlet of integral two. 
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Figure 3.7 Expanded area of the 
1
H-NMR spectra of 3.8 (bottom spectrum), 3.5 (middle spectrum) and 3.2 (top spectrum) 
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3.1.2.4 Complexes 3.6 and 3.9 
 
Scheme 3.5 One pot synthesis of 3.6 and 3.9 
Scheme 3.5 shows the one pot synthesis of 3.6 and 3.9.  A yield of 15% for mono-Pt and 
5% for di-Pt was achieved.  Figure 3.8 shows the 1H-NMR spectra of 3.9 (bottom 
spectrum), 3.6 (middle spectrum) and 3.3 (top spectrum).  The complex is derived 
analogously to 2.2 and so the same conclusions can be drawn as to interpreting the 1H-
NMR.  Proton 5 of Figure 3.8 has platinum satellites (3JH-Pt 43.5 Hz) and so can easily be 
assigned.  The additional splitting is due to the fluorine atoms. 
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Figure 3.8 Expanded area of the 
1
H-NMR spectra of 3.9 (bottom spectrum), 3.6 (middle spectrum) and 3.3 (top spectrum) 
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3.2 Absorption Spectroscopy  
Table 3.1 UV-visible absorption data for the complexes 
Complex max / nm  ( / M
–1cm–1) 
2.14 (-H) 341 (13435), 353 (12030), 398 (4996), 436 (4027) 
3.4 (-Me) 307 (22588), 367 (14672), 388 (9266), 442 (5864) 
3.5 (-OMe) 337 (20274), 367 (10288), 429 (8041), 452 (6877) 
3.6 (-F) 358 (12759), 392 (7988), 429 (6124) 
2.20 (-H) 336 (23380), 375 (17581), 453 (17044), 502 (7288), 521 (6264) 
3.7 (-Me) 322 (24965), 339 (24026), 431 (12523), 448 (12895), 528 (6495) 
3.8 (-OMe) 321 (21362), 370 (26295), 440 (12464), 504 (7762), 540 (8373) 
3.9 (-F) 320 (6902), 363 (5634), 447 (5143), 515 (1938) 
 
The absorption data for the complexes is shown in Table 3.1.  Chart 3.1 shows the UV 
spectra of the mono-Pt complexes.  The most red shifted are the complexes containing 
methoxy or methyl substituents.  The complex containing the fluorine substituent is the 
most blue shifted.  The same can be said of the di-Pt complexes, which are shown in 
Chart 3.2. The di-Pt complexes are significantly red shifted compared to the mono-Pt 
complexes.  
 
There is trend in absorbance of F < H < CH3 < OMe.  This is due to the HOMO and LUMO 
orbitals being affected by the electron donating and withdrawing groups.  Fluorine is an 
electron withdrawing group, so will therefore decrease the delocalised electron density in 
the aromatic ring.   The HOMO, which is generally localised on the phenyl moiety, is 
reduced, increasing the HOMO-LUMO energy gap.  Hence the compound containing the 
fluorine substituent has the lowest wavelength of absorption.  Methoxy and methyl are 
electron donating groups and so destabilise the HOMO, with the methoxy group showing 
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the biggest effect.  This too is reflected in the fact that the compounds containing these 
groups have the highest wavelength of absorption. 
 
Chart 3.1 UV spectra of the mono-Pt complexes using substituted 2,5-diphenylpyrazines 
 
Chart 3.2 UV spectra of the di-Pt complexes using substituted 2,5-diphenylpyrazines 
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As mentioned previously, two metals in the complex cause a further red-shift.  This is 
shown in Chart 3.3 which contains the UV data for the proligand 3.2 and its mono-Pt and 
di-Pt derivatives (Figure 3.9).  The data shows a definite red-shift from the mono-Pt to the 
di-Pt complex.  The extinction coefficients are higher for the di-Pt derivatives compared to 
their mono-Pt counterparts with the exception of 3.9 which is significantly reduced. 
 
Figure 3.9 Proligand 3.2 and its mono-Pt (3.5) and di-Pt (3.8) derivatives 
 
Chart 3.3 UV spectra for 3.2, 3.5 and 3.8 
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3.3 Photoluminescent properties 
All eight complexes are luminescent in solution at room temperature.  The complexes 
were unable to be degassed before measurements were taken and so comments on the 
intensity of the emission cannot be made as the quenching by oxygen will have an effect 
on the intensity.  The emission data for the compounds are compiled in Table 3.2, and the 
spectra are shown in Chart 3.4 and Chart 3.5.  The trends in emission maxima are quite 
similar to those observed in the absorption spectra.  In particular, it may be immediately 
seen that, for a given ligand, the spectrum of the dinuclear complex is significantly red-
shifted compared to that of the corresponding mononuclear complex, with a difference of 
around 65-80nm between the mono-Pt and di-Pt species. 
Table 3.2 Emission data for the complexes 
 Emission (nm) 
Complex Mono-Pt Di-Pt 
2.14 & 2.20 (-H) 566 629 
3.4 & 3.7 (-Me) 574 642 
3.5 & 3.8 (-OMe) 590 667 
3.6 & 3.9 (-F) 558 623 
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Chart 3.4 Emission spectra of the mono-Pt complexes using substituted 2,5-diphenylpyrazines 
 
Chart 3.5 Emission spectra of the di-Pt complexes using substituted 2,5-diphenylpyrazines 
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3.4 Concluding Discussion 
Four mono-Pt and four di-Pt complexes were prepared by a ‘one pot’ synthesis which 
yielded both the mono and di-Pt complexes in one synthesis.  The complexes were 
separated by column chromatography.  The UV data shows that changing the substituents 
on the proligand does affect the absorption and emission of the compound.  By adding 
electron donating groups such as methoxy, there is a significant red-shift.  Electron 
withdrawing groups such as fluorine cause a blue shift in the compound.  Also an even 
greater red shift is achieved when there are two metals present in the compound in the 
order of 85-88 nm. 
 
This trend was also shown by Laskar and co-workers9.  They synthesised a series of 2-
phenylbenzothiazolato substituted platinum(II) complexes with H (3.16), OMe (3.17), F 
(3.18) and CF3 (3.19) substituents. 
 
 
Figure 3.10 The series of 2-phenylbenzothiazolato substituted platinum(II) complexes 
Complexes 3.18 and 3.19 are more blue shifted due to the electron withdrawing fluorines, 
compared to 3.16 and 3.17 which have electron donating substituents.  
95 
 
 
 
 
 
 
Chapter 4: Luminescent iridium(III) 
complexes incorporating 
cyclometallated N^C^N coordinating 
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4 Luminescent iridium(III) complexes incorporating 
cyclometallated N^C^N coordinating 1,3-di(2-pyridyl)benzene 
derivatives 
The aim of this section is to synthesise a series of bis- Ir (III) complexes where metal 
centres are rigidly connected by a cyclometallating bridging ligand.  Examples of such 
complexes are very rare in the literature42,24,23,87.  This is probably due to the quite 
complex stereochemistry associated with the use of two or more metal centres. In this 
case, bidentate ligands are used.  The synthesis is accompanied by the formation of a 
mixture of diasteromers making analysis and characterisation of the molecules difficult.  
For example, Tsuboyama and co-workers describe the synthesis of a red-phosphorescent 
dinuclear iridium complex88(Figure 4.1).  The desired di-iridium complex was isolated in 
only a 3% yield. 
 
Figure 4.1 (ppy)2Ir(µ-BPB)Ir(ppy)2 
One way to reduce this problem is by using symmetrical terdentate proligands.  For 
example Figure 4.2 shows a variety of non-chiral mono Ir(III) complexes based on 1,5-
bis(2-pyridyl)benzene that Brulatti and co-workers have recently reported23. This 
terdentate cyclometallating ligand is used in conjunction with bidentate cyclometallating 
unit as well as chloride ion yielding a neutral molecule. The complexes of this kind are 
highly luminescent with quantum yields in the region of 0.75. 
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Figure 4.2 Mononuclear Iridium(III) complexes described by Brulatti and co-workers, and their 
preparation via the chloro-bridged dimers 
We therefore decided to use this N^C^N motif and our bisbidentate bridging ligands to 
create rigid bimetallic complexes. It is important to mention that due to trans-effect of 
anionic carbon atoms in the ligands only cis-arrangement of these carbons takes place 
(Figure 4.3). 
 
Figure 4.3 The trans effect only allows the cis arrangement 
 
This is a unique feature which distinguishes these molecular systems from classical 
polypyridine-based architectures, known to produce mixtures of a variety of isomers. In 
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our targeted bis iridium (III) complexes (figure) the formation of only one stereoisomer is 
expected. 
 
 
Figure 4.4 Targeted dinuclear iridium(III) complexes.  Note that all coordinated carbon atoms are trans 
to each other. 
In our systems we vary the central bis-bidentate cyclometallating bridging unit, while the 
symmetrical terdentate NCN proligand is the same for all systems. Aliphatic hexyl chains 
as well as tert-butyl groups are introduced in order to increase solubility and also to 
simplify the aromatic region of the 1H-NMR spectra to aid characterisation. In this chapter 
we describe our attempts to synthesise these novel structures. 
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4.1 Synthesis 
4.1.1 Proligand synthesis 
4.1.1.1 Bis-bidentate cyclometallating proligands 
 
Figure 4.5 Synthesis of the starting proligands 
Three ligands with linking pyrazine (4.17), pyrimidine (4.18) and pyridazine (4.16) 
heterocycles were prepared by Suzuki –Miyaura coupling of 4-tert-butylphenylboronic acid 
(4.12) and the corresponding dihilides (4.13, 4.14, and 4.15). Both the bromo and 
chloroderivatives of diazines can be used in this step. The starting 4-tert-
butylphenylboronic acid (4.12) was prepared via lithium-halogen exchange followed by 
treatment with triisopropylborate and subsequent hydrolysis      
4.1.1.2 Terdentate proligands 
There are five synthetic steps involved to achieve the N^C^N proligand.  Scheme 4.1 
shows the steps involved to synthesise the terdentate proligand.  The proligand contains 
fluorine groups at the C4 and C6 positions as competitive cyclometallation can then be 
avoided.  The addition of the alkyl chain on the phenyl moiety, and the tert-butyl groups on 
the pyridine moieties is to improve the solubility of the resultant complex.  In addition, the 
1H-NMR spectrum of the proligand is made easier to interpret as there are only 4 aromatic 
signals and less complicated spin-splitting patterns. The synthesis starts with 2,6-
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difluorophenol (4.18) which is alkylated by 1-bromohexane in presence of potassium 
carbonate (step A) to give 1,3-difluoro-2-(hexyloxy)benzene (4.19). 
 
Scheme 4.1 Synthesis of the terdentate ligand 
Step B is to synthesise the boronic acid 4.20 using n-butyllithium and triisopropyl borate.  
The fluorine groups are ortho directing ensuring that the synthesis takes place at the C1 
or C3 position.  Step C is a Suzuki reaction using 4-tert-butyl-2-chloropyridine, the boronic 
acid 4.20, potassium phosphate and tetrakis(triphenylphosphine)palladium(0) in 1,4-
dioxane, to attach one of the 4-tert-butylpyridine moieties (4.21).  Step D is another 
boronic acid synthesis. We found that the addition of N,N,N’,N’’,N’’-
pentamethyldiethylenetriamine (4.22) is needed at this step. If the amine is not used a 
mixture of two boronic acids is formed. The undesired second boronic acid is a product of 
competitive ortho-lithiation directed by pyridine ring. The amine is used at this stage to 
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make the lithium more reactive.  If the lithium is more reactive it will react quicker ortho to 
fluorine which is a stronger ortho director giving the desired boronic acid 4.23.  Step E is a 
final Suzuki synthesis to attach the second 4-tert-butylpyridine moiety, giving the 
terdentate proligand 4.24. 
4.1.2 Iridium(III) complex synthesis 
4.1.2.1 Di-chloro-bridged intermediate 
The chloride-bridged intermediate (4.26) was synthesised by reacting 4.25 with iridium 
chloride trihydrate23 in a mixture of ethoxyethanol and water (3:1 ratio) and heating under 
reflux for 21 hours to give a yield of 84% (Scheme 4.2). 
 
Scheme 4.2 Synthesis of dichloro-bridged intermediate 
 
In contrast to previous reports that the chloride-bridged intermediate is too insoluble to 
obtain an 1H-NMR42, in our case the intermediate was found to be very soluble in CDCl3 
and allowed us to record 1H, 19F and 13C-NMR spectra.  Figure 4.6 shows the spectra of 
both the proligand (4.25, bottom spectra) and the chloride-bridged intermediate (4.26, top 
spectra).  As can be seen clearly, the reaction took place as the triplet for the proton on 
the aromatic moiety is no longer present and the protons on the pyridine moiety have 
shifted.  Protons B and C are more shielded and proton A is more deshielded compared 
to the chemical shifts of corresponding protons in the proligand. 
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Figure 4.6 
1
H-NMR spectra of 4.25 (bottom spectra) and 4.26 (top spectra) 
 
The 19F spectra of the complex and the ligand also support the formation of 
cyclometallated complex. It can be seen (Figure 4.7) that the signal of F atoms in the 
ligand 4.25 is a doublet due to coupling with the proton 4. Upon coordination to Iridium 
(4.26) proton 4 is displaced by Ir and the signal becomes a singlet. The signal is also 
experiencing a large change in chemical shift value. 
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Figure 4.7 
19
F-NMR spectra of 4.25 (bottom spectra) and 4.26 (top spectra) 
The NMR characterization of dichlorobridged Ir(III) complexes formed by NCN terdentate 
ligands was unprecedented in the literature. As a result of the work described above, we 
prepared and fully characterised key starting materials to be used in the following work. 
4.1.2.2 Introduction of the central bridging unit 
In our synthesis we adapted the methodology for mono Ir(III) complexes described by 
Brulatti and co-workers23.  The method involves heating under reflux the mixture of 
dichlorobridged intermediate (4.26) with bidentate cyclometallating ligands in the presence 
of silver triflate as a chloride scavenger. Importantly, under these conditions, no 
scrambling of the ligands was registered. Below we describe the results of our attempts to 
synthesise bimetallic systems using three types of bridging ligands. 
4.1.2.3 Pyrimidine-based system 4.27 
 
Adapting known reaction conditions to our systems, the iridium(III) complexes were 
obtained by refluxing a mixture of 4.26 and a bis-bidentate proligand in the presence of 
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silver triflate in toluene. Initially the yields were quite low; but we optimised the conditions 
and achieved yields in the range of 50-80%. The optimised conditions are as follows- the 
ratio of dichloro-bridged intermediate and the bridging ligands was 1:1 which corresponds 
to one equivalent of bidentate coordinating unit per iridium atom. Three equivalents of 
silver triflate were used. The reaction time was in the range of 8-14 hours. After the 
reaction, the mixture was treated with excess of 2M hydrochloric acid. Column 
chromatography was found to reduce the yields and so best to be avoided. 
 
Using the conditions described above, and 4,6-di(4-terbutylphenyl)pyrimidine (4.18) as a 
bridging ligand, the targeted complex 4.27 was obtained in 48% yield as a single isomer 
(Scheme 4.3 Synthesis of 4.27). The complex was characterised by 1H, 19F and 13C NMR. 
 
Scheme 4.3 Synthesis of 4.27 
The 1H NMR spectrum of the complex is depicted in Figure 4.8. The signals of all 
hydrogen environments can be found on the spectrum. The characteristic feature of the 
spectrum is that proton in the position two of the pyrimidine ring (labelled 5) has a very 
high chemical shift value of 11.8 ppm. This is due to the close proximity of the chlorides. 
Another characteristic signal at 6.3 ppm is assigned to proton which is in ortho position to 
iridium atom (labelled 1). The complex is stable at room temperature as a solid. For a 
solution of 4.27 in CDCl3, no signs of isomerisation or degradation were registered after 1 
day in day light. 
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Figure 4.8 
1
H-NMR of complex 4.27 
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4.1.2.4 Pyridiazine based system 4.29 
Identical conditions described for pyrimidine-based systems were applied to the 
pyridazine bridging ligand (4.16). We immediately realised that the solubility of the product 
was very different to pyrimidine-linked isomer 4.27. We found for example that 4.29 is 
soluble in methanol while 4.27 is very insoluble in this solvent. This suggests that the 
product is ionic in character. One explanation would be that the iridium centres share one 
chloride ligand and this leads to an overall positively-charged complex. This behaviour 
was previously observed by Slater and co-workers89 in corresponding Pd(II) complexes 
using the same bridging ligand. The counter ion in our reaction can be either chloride or 
triflate. To eliminate this ambiguity we decided to treat the product with excess of KPF6 in 
order to prepare a uniform sample with hexafluorophosphate counter ion. The overall 
reaction is depicted in Scheme 4.4. 
 
 
Scheme 4.4 Synthesis of complex 4.29 
The yield of the reaction was very low, 3-7% for three attempts. At the moment we cannot 
comment why the yield is so low. Figure 4.9 and Figure 4.10 shows the 1H-NMR spectra 
of 4.29.  As with previous case’s, all signals can be assigned. 19F NMR shows signals of 
fluoro groups in the NCN ligands as a singlet at – 125.8 ppm. There is also the signal of 
PF6 at -72.6 ppm, which is as a doublet 1JF-P= 758 Hz.   
4,7 
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Figure 4.9 
1
H-NMR spectra of complex 4.29 
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Figure 4.10 expanded aromatic region of the 
1
H-NMR spectra for complex 4.29 
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The high resolution mass spec did confirm the correct mass for 4.29 of 1756 gmol-1.  
Figure 4.11 shows the spectrum for the complex.  It shows peaks at the correct mass for 
the complex but also a high abundance of a mass at 1721.  This could be attributed to the 
presence of the complex with just one bridging chlorine atom as shown in Scheme 4.4.
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Figure 4.11 High resolution mass spec for compound 4.29 
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4.1.2.5 Pyrazine-based system 4.30 
 
Scheme 4.5 Synthesis of complex 4.30 
Scheme 4.5 shows the synthesis of the pyrazine-linked diiridium complex 4.30. The first 
attempts to make this complex provided very low yields (5-10%). Based on the NMR data 
we can conclude that the complex did form as shown in Figure 4.12 and Figure 4.13. 
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Figure 4.12 
1
H-NMR spectrum of pyrazine-bridged diiridium complex 4.30 
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Figure 4.13 Aromatic region of 
1
H-NMR spectrum of pyrazine-bridged diiridium complex 4.30 
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In order to try to establish if photodegradation was occurring, 2 identical samples were 
prepared by dissolving approximately 10-14 mg of the complex into 2 cm3 of CDCl3.  This 
was then divided into two equal parts and placed into NMR tubes. One tube was wrapped 
in aluminium foil. Both tubes were placed on a windowsill between the hours of 10 am and 
3 pm on quite a sunny day (we appreciate that we do not know exactly the spectral 
composition and intensity of the radiation experienced by the sample).  The 1H-NMR 
spectra were recorded at intervals (Figure 4.14). The NMR spectrum of the sample 
protected from the sun-light did not change over time. Conversely, the sample which was 
exposed to sun-light underwent a transformation. There is a formation of several species, 
but eventually, after approximately 15-24 hours the sample “stabilises” and is no longer 
changing.  From this it is clear that the complex breaks down or isomerises when exposed 
to light.  Similar behaviour was previously recorded for monometallic complexes 23.  Based 
on this data, the main degradation pathway is probably the loss of chloride atoms para to 
the cyclometallating carbon atoms.  It is possible to exchange chlorides with neutral 
ligands such as acetonitrile to obtain dicationic complexes, which may be more stable. At 
the moment this is only a hypothesis.  More detailed investigation is needed to determine 
the products and causes of photoisomerisation/transformation.  Unfortunately, due to time 
constraints, we were not able to study this phenomena in more detail. 
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Figure 4.14 
1
H-NMR spectra of complex 4.30 after exposure to sun-light at various intervals 
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4.2 Concluding discussion 
In this chapter we describe the synthesis of three unprecedented bimetallic Ir(III) 
complexes formed by ditopic cyclometallating C^NN^C bridging ligands and a terdentate 
NCN cyclometallating auxiliary ligand.  The systems were carefully designed to produce a 
single isomer.  Pyrimidine, pyrazine and pyridazines were tested as linking heterocycles 
and found to have a drastic influence on the outcome of the reaction.  
 
The pyrimidine-linked complex gave the expected result with two metal centres connected 
by the linker and both metal centres include one terdentade, one bidentate and chloro 
ligands. This neutral complex is stable both in solid state and in solution and is intensely 
luminescent.  The pyrazine-linked analogue was synthesised successfully, but was found 
to rapidly isomerise/decompose in CDCl3 solution by the action of light leading to non-
emissive products.  The metal centres in the pyridazine-linked complex tend share a 
chloride ion to yield a positively charged ion. 
  
These findings show that by using pyrimidine, pyrazine or pyridazine linkers, three distinct 
families of compounds rather than just structural isomers are obtained. The main result of 
this part of the work is that we collected valuable synthetic information, which will allow 
further, more detailed studies of these interesting complexes in the future.  
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Chapter 5: Summary 
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5 Summary 
The purpose of this work was to synthesise and investigate the properties of a new class 
of cyclometallated Pt(II) and Ir(III) complexes with a rigid polymetallic assembly.  The first 
part of the work was to investigate how the bridging ligand affects the luminescent 
properties of the mono-Pt and di-Pt systems.  Using diphenylpyrazines to generate 
dinuclear platinum(II) complexes, through metallation of the two pendent phenyl rings and 
binding of the metal ions to the two nitrogen atoms of the central heterocycle.  Both the 
2,3- and 2,5-substituted isomers of diphenylpyrazine can be employed, along with 
diphenylquinoxaline and derivatives in which the phenyl rings are interlinked through their 
ortho positions.  The introduction of the second metal ion leads, for all six ligands 
investigated, to a significant stabilization of the LUMO.  In contrast, the HOMO energy 
seems to be influenced rather little.  The decreased HOMO–LUMO gap that ensues leads 
to red-shifted absorption and emission spectra for the dinuclear complexes compared to 
their mononuclear analogues.  Meanwhile, the increased conjugation within the 
heterocycle on going from a pyrazine through quinoxaline to a phenazine unit (as in L6) 
has a much more significant effect on the LUMO, leading to the progressive shift towards 
the red region observed in the optical spectra.  Dinuclear cyclometallated complexes are 
shown to offer interesting potential for obtaining phosphorescent materials that both 
absorb strongly and emit brightly at unusually low energies.  Further derivatisation of the 
diarylpyrazine unit can be confidently expected to lead to further new compounds with 
opportunities for controlling excited states for contemporary applications, such as in 
imaging and light-emitting displays. 
 
In the second part of this work, four mono-Pt and four di-Pt complexes were prepared by a 
‘one pot’ synthesis which yielded both the mono and di-Pt complexes in one synthesis.  
The complexes were separated by column chromatography.  The study was to determine 
how much luminescence was affected by changing the substituents on the proligand.  The 
UV data shows that changing the substituents on the proligand does affect the absorption 
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and emission of the compound.  By adding electron donating groups such as methoxy, 
there is a significant red-shift.  Electron withdrawing groups such as fluorine cause a blue 
shift in the compound.  Also an even greater red shift is achieved when there are two 
metals present in the compound.  This behaviour is an effective tool for the fine-tuning of 
luminescence properties. 
 
In the final part of the work, we described the synthesis of three unprecedented bimetallic 
Ir(III) complexes formed by ditopic cyclometallating C^NN^C bridging ligands and a 
terdentate NCN cyclometallating auxiliary ligand.  The systems were carefully designed to 
produce a single isomer.  Pyrimidine, pyrazine and pyridazines were tested as linking 
heterocycles and found to have a drastic influence on the outcome of the reaction.  These 
findings show that by using pyrimidine, pyrazine or pyridazine linkers, three distinct 
families of compounds rather than just structural isomers are obtained. The main result of 
this part of the work is that we collected valuable synthetic information, which will allow 
further, more detailed studies of these interesting complexes in the future.  
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6 Experimental 
NMR spectra were recorded using a Jeol JNM Ex270 instrument at 270 MHz and 68 MHz 
or a Jeol JNM-ECS400 instrument at 400 MHz and 100 MHz, as specified, for 1H- and 
13C- NMR respectively. 1H NMR data are reported as follows: chemical shift (δ, ppm), 
multiplicity (s = singlet, d = doublet, t =triplet, q = quartet, m = multiplet), integration, 
coupling constants reported in Hz. Data for 13C NMR are reported in terms of chemical 
shift (δ, ppm). UV/Visible spectra were run on a Varian Cary 50 UV-Visible 
spectrophotometer (range 600-200 nm), using a 10mm quartz cell at room temperature 
(18-22 °C). Infrared spectra were obtained using Durascope diamond ATR system on a 
Perkin Elmer RX1 FTIR spectrometer. Positive and negative electrospray ionisation mass 
spectrometry (ESI-MS) was conducted using a Thermo LCQ Advantage spectrometer by 
direct injection and high resolution mass spectrometry (HRMS) was performed by the 
EPSRC National Mass Spectrometry Service (Swansea, Wales) on a Thermofisher LTQ 
Orbitrap XL mass spectrometer low-resolution electrospray (ESI) or high-resolution 
nanoelectrospray (NSI) ionization techniques.  Melting points were taken on a SRS 
DigiMelt MPA161 digital melting point apparatus (200 to 250 VAC 1/2AMP 50-60Hz). CHN 
analysis was performed by Richard Baron from the department of Advanced Materials and 
Chemical Analysis in the School of Chemistry, Newcastle University using a Carlo Erba 
1108 Elemental Analyser controlled with CE Eager 200 software, run in accordance with 
the manufacturer's instructions and samples weighed using a certified Mettler MX5 
Microbalance. 
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6.1 Ligand Synthesis 
6.1.1 Compound 2.1 
Phenylboronic acid (1 g, 8.20 mmol) and 4,6-dichloropyrimidine 
(469 mg, 3.15 mmol) were dissolved in 1,4-dioxane (25 cm3) and 
the reaction mixture was then deairated by bubbling N2 through the 
mixture for 10 minutes.  Aqueous K2CO3 solution (2M, 9 cm
3, 18.8 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (220 mg, 0.19 mmol) were added and the 
mixture deairated for a further 15 minutes.  The reaction mixture was then stirred at 95C 
under N2 for 24 h.  The solvents were removed under vacuum and DCM (35 cm
3) was 
added.  The organic layer was separated, washed with water (3  35 cm3), dried over 
MgSO4, filtered and evaporated to dryness.  The product was then purified by column 
chromatography using silica gel and ethyl acetate / DCM (1:4 ratio) as the eluent; yield 
680 mg, 93%.  1H NMR (CDCl3, 270MHz) δ 9.31 (1H, d, J = 1.2 Hz), 8.16-8.12 (4H, m), 
8.10 (1H, d, J = 1.5 Hz), 7.55-7.50 (6H, m).  13C NMR (CDCl3, 68 MHz) δC 164.8, 159.3, 
137.1, 131.0, 129.1, 127.2, 112.9.  IR = 2958.8, 2902.9, 2866.1, 1583.7, 831.6, 694.2 cm-
1.  MS (ESI): m/z 233 [M+H]+.  Elemental analysis calcld for C16H12N2: C 82.73, H 5.21, N 
12.06 %; found C 82.85, H 5.33, N 11.92 %90. 
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6.1.2 Compound 2.2 
Method A. Suzuki synthesis: Phenylboronic acid (1 g, 8.20 mmol) 
and 2,5-dibromopyrazine (750 mg, 3.15 mmol) were dissolved in 
1,4-dioxane (25 cm3) and the reaction mixture then degassed by 
bubbling N2 through it for 10 minutes.  2M aqueous K2CO3 solution 
(9 cm3, 18.84 mmol) and tetrakis(triphenylphosphine)palladium(0) (6% mol, 220 mg, 0.19 
mmol) was added and the reaction mixture degassed for a further 15 minutes.  The 
reaction mixture was then stirred at 95oC for 24 hours under N2.  On cooling, water was 
added and the resulting precipitate was filtered and dried.  The residue was then 
recrystallized from ethanol and activated charcoal.  Yield 390 mg, 53%.  Melting point 
194-197°C (lit. 194°C).  1H NMR (CDCl3, 270 MHz) δH 9.07 (2H, d, J = 0.7 Hz), 8.08–8.03 
(4H, m), 7.56-7.46 (6H, m).  13C NMR (CDCl3, 100 MHz) δ 150.8, 141.4, 136.4, 129.9, 
129.2, 126.9. 
 
Method B. Synthesis from 2-bromoacetophenones: 2-Bromoacetophenone (18 g, 
0.09 mol) was dissolved in ethanol (150 cm3) and aqueous ammonia (35 %, 100 cm3) was 
added.  The solution was left stirring at 50°C overnight.  Hydrogen peroxide (30 cm3) was 
then added and the mixture was left stirring at room temperature for 2 days. The 
precipitate was filtered off and recrystallized from acetic acid.  Yield 2.6 g, 13 %.  1H NMR 
(CDCl3, 400MHz) δ 9.08 (2H, s), 8.07-8.05 (4H, m), 7.56-7.46 (6H, m). 
 13C NMR (CDCl3, 
400MHz) δ150.8, 141.4, 136.37, 129.9, 129.2, 126.9
85,86
. 
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6.1.3 Compound 2.4 
A solution of 9,10-phenanthenequinone (5.3 g, 25 mmol) and ethanol (100 
cm3) was refluxed for 5 minutes.  Ethylenediamine (1.9 g, 32 mmol) was 
added and the solution heated under reflux for 1 hour.  Acetic acid (200 
cm3) was added and the solution heated under reflux for 15 hours.  The 
volume of the solution was then reduced to 150 cm3 by rotary evaporation and again 
heated under reflux for 1 hour.  The solution was then allowed to cool to room 
temperature and the precipitate solid was filtered.  Yield 3.09 g, 46%.  1H-NMR (270 MHz, 
CDCl3) δH 9.22 (2H, dd, J = 7.92, 1.7 Hz), 8.90 (2H, s), 8.63 (2H, d, J = 7.42), 7.77 (4H, 
m).  13C NMR (CDCl3, 400MHz) δC 143.60, 141.55, 131.51, 129.97, 129.68, 127.79, 
125.47, 122.8574. 
 
6.1.4 Compound 2.6 
A solution of 9,10-phenanthenequinone (2.08 g, 0.01 mol) and 
ethanol (180 cm3) was refluxed until dissolved.  O-phenylenediamine 
(1.08 g, 0.01 mol) and ethanol (20 cm3) was added and the solution 
heated under reflux for a further 10 minutes.  A drop of conc. HCl was 
added and a precipitate is formed.  The solution was then heated under reflux for 2 hours.  
The precipitate solid was filtered and washed with ethanol.  Solid was then recrystallized 
from chloroform.  Yield 1.97 g, 70 %.  1H-NMR (400 MHz, CDCl3) δH 9.41 (2H, dd, J = 
7.79, 1.8 Hz), 8.57 (2H, d, J = 7.79 Hz), 8.35-8.31 (2H, m), 7.87-7.83 (1H, m), 7.82-7.73 
(3H, m).  13C NMR (CDCl3, 400MHz) δC 142.52, 142.27, 132.13, 130.40, 129.84, 129.54, 
128.02, 126.34, 123.0075. 
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6.1.5 Compound 3.1 
4’-methylacetophenone (27 g, 0.2 mol) was dissolved in diethyl ether (400 
cm3).  Bromine (32 g, 0.2 mol) was added drop wise.  The solution was then 
washed consecutively with water, sodium bicarbonate and water (50 cm3 
portions) and the diethyl ether evaporated. Yield 36 g, 84 %.  1H NMR 
(CDCl3, 400MHz) δ 7.88 (2H, d, J = 7.5 Hz), 7.28 (2H, d, J = 7.2 Hz), 4.56 (2H, s), 2.34 
(3H, s)91. 
The 2-bromo-1-(p-tolyl)ethanone (36 g, 0.17 mol) was 
dissolved in ethanol (250 cm3) and Aqueous ammonia (35 %, 
140 mL) was added.  The solution was left stirring at 50°C 
overnight.  Hydrogen peroxide (20 cm3) was then added and 
left stirring at room temperature for 2 days.  The precipitate was recrystallized from acetic 
acid, washed with ethanol and dried.   Yield 4.8 g, 11 %.  Melting point 199-202oC.  1H 
NMR (CDCl3, 400MHz) δ 9.02 (2H, s), 7.95 (4H, d, J = 9.0 Hz), 7.32 (4H, d, J = 8.4 Hz), 
2.43 (6H, s).  13C NMR (CDCl3, 400MHz) δC 157.9, 143.1, 141.6, 138.5, 129.1, 125.9, 
106.8, 57.1, 44.0, 12.392. 
 
 
 
 
 
 
 
 
 
126 
 
6.1.6 Compound 3.2 
4’-methoxyacetophenone (30 g, 0.20 mol) was dissolved in diethyl ether (400 
cm3).  Bromine (32 g, 0.20 mol) was added drop wise.  The precipitated solid 
was then filtered and dried.  Yield 30 g, 67 %.  1H NMR (CDCl3, 400MHz) δ 
7.83 (2H, d, J = 8.2 Hz), 7.10 (2H, d, J = 8.7 Hz), 4.56 (2H, s), 3.83 (2H, s)92. 
 
The 2-bromo-4’-methoxyacetophenone (10 g, 0.04 mol) 
was dissolved in ethanol (150 cm3) and aqueous ammonia 
(35 %, 100 cm3) was added.  The solution was left stirring 
at 50°C overnight.  Hydrogen peroxide (30 cm3) was then 
added and left stirring at room temperature for 2 days. The 
precipitate was filtered off, washed with ethanol. The product was then purified by 
recrystallization from acetic acid.  Yield 2.4 g, 21%. Melting point 226-228°C.  1H NMR 
(CDCl3, 400MHz) δ 8.96 (2H, s), 8.00 (4H, d, J = 10.4 Hz), 7.03 (4H, d, J = 10.9 Hz), 3.87 
(6H, s).  13C NMR (CDCl3, 400MHz) δC 161.0, 149.7, 140.6, 129.1, 128.1, 114.6, 55.5
92. 
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6.1.7 Compound 3.3 
4’-fluoroacetophenone (25 g, 0.18 mol) was dissolved in diethyl ether (400 
cm3).  Bromine (29 g, 0.18 mol) was added drop wise.  The solution was then 
washed consecutively with water, sodium bicarbonate and water (50 cm3 
portions).  2-propanol (100 cm3) was added and the flask was then placed 
into ice.  The resulting precipitate was then filtered and dried. Yield 11.5 g, 30 %.  1H NMR 
(CDCl3, 400MHz) δ 8.12 (2H, m), 7.35 (2H, m), 4.56 (2H, s)
93. 
 
  The 2-bromo-1-(4-fluorophenyl)ethanone (11.5 g, 0.05 
mol) was dissolved in ethanol (150 cm3) and aqueous 
ammonia (35 %, 100 mL) was added.  The solution was left 
stirring at 50 oC overnight.  Hydrogen peroxide (30 cm3) was 
then added and left stirring at room temperature for 2 days. The precipitate was filtered 
and dried.  Yield 1.26 g, 10 %. Melting point 229-232 °C.  1H NMR (CDCl3, 400MHz) δ 
9.01 (2H, s), 8.07-8.03 (4H, m), 7.25-7.19 (4H, m).  13C NMR (CDCl3, 400MHz) δC 140.9, 
128.8, 128.7, 116.4, 116.1 
 
6.1.8 Compound 4.16 
 4-tert-butylphenylboronic acid (1 g, 5.65 mmol) and 
3,6-dichloropyridazine (323 mg, 2.17 mmol) were 
dissolved in 1,4-dioxane (60 cm3) and the solution then degassed by bubbling N2 through 
it for 10 minutes.  2M aqueous K2CO3 solution (7 cm
3, 13 mmol) and 
tetrakis(triphenylphosphine) palladium (6% mol, 150 mg, 0.13 mmol) was added and the 
solution degassed for a further 15 minutes.  The reaction mixture was then stirred at 95oC 
for 24 hours under N2.  On cooling, product had crashed out.  Filtered and washed with 
methanol. Yield 692 mg, 93%.  1H-NMR (400 MHz, CDCl3) δ 8.09 (d, 4H, J = 8.4), 7.89 (s, 
2H), 7.55 (d, 4H, J = 6.4), 1.37 (s, 18H). 
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6.1.9 Compound 4.17 
 Potassium phosphate (2.6 g, 12.42 mmol) was 
dissolved in water (10 cm3) and the solution was 
degassed by bubbling nitrogen through the mixture for 
10 minutes.  A mixture of (4-tert-butylphenyl)boronic acid 
(1.1 g, 6.21 mmol), 2,5-dibromopyrazine (985 mg, 4.14 
mmol) and 1,4-dioxane (50 cm3) was degassed for 10 minutes.  Tetrakis triphosphine 
palladium(0) (289 mg, 0.25 mmol) and the solution of K3PO4 was then added and 
degassed for a further 15 minutes.  The solution was then stirred under nitrogen at 105 oC 
for 24 hours.  On cooling a precipitate started to form.  Water was added and more 
precipitate was formed.  The precipitate was filtered using Buchner filtration and was 
washed with water.  The solid was recrystallized from acetic acid by hot filtration.  Yield 
623 g, 45 %.  1H-NMR (400 MHz, CDCl3) δ 9.04 (2H, d, J = 1.4 Hz), 7.99 (4H, d, J = 8.2 
Hz), 7.54 (4H, d, J = 8.7 Hz), 1.36 (18H, s).  13C NMR (CDCl3, 400MHz) δC 153.10, 
150.42, 141.13, 133.63, 126.56, 126.13, 34.90, 31.35. 
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6.1.10 Compound 4.18 
4-tert-butylphenylboronic acid (1 g, 5.65 mmol) and 4,6-
dichloropyrimidine (323 mg, 2.17 mmol) were dissolved 
in 1,4-dioxane (25 cm3) and the solution then degassed 
by bubbling N2 through it for 10 minutes.  2M aqueous 
K2CO3 solution (7 cm
3, 13.02 mmol) and tetrakis(triphenylphosphine)palladium(0) (154 
mg, 0.13 mmol) was added and the solution degassed for a further 15 minutes.  The 
reaction mixture was then stirred at 95oC for 24 hours under N2.  1,4-Dioxane was 
removed and the product dissolved in DCM (25 cm3).  The solution was washed with 
water (3 x 25 cm3), dried over MgSO4 and the solution was then evaporated to dryness.  
The residue was purified by column chromatography using silica gel and ethyl 
acetate/DCM (1:4 ratio) as the eluent.  The column chromatography was then repeated 
using ethyl acetate/hexane (1:4 ratio) as the eluent.  Yield 560 mg, 75%.  Melting point 
154-157oC.  1H NMR (CDCl3, 270MHz) δ 9.26 (1H, d, J = 1.2 Hz), 8.09-8.03 (5H, m), 7.54 
(4H, d, J = 8.7 Hz), 1.35 (18H, s).  13C NMR (CDCl3, 68MHz) δ164.5, 159.2, 154.4, 134.3, 
127.0, 126.1, 112.3, 34.9, 31.3.  IR = 2958, 1583, 1505, 1464, 1362 cm-1.  MS (ESI): m/z 
345 [M+H]+.  Elemental analysis calcld for C24H28N2: C 83.68, H 8.19, N 8.13; found C 
83.43, H 8.64, N 7.6843. 
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6.1.11 Compound 4.19 
A mixture of K2CO3 (41.4 g, 300 mmol), acetonitrile (100 cm
3), 2,6-
difluorophenol (13 g, 100 mmol) and 1-bromohexane (16.5 g, 100 
mmol) was heated under reflux for 21 hours.  Petroleum ether (100 
cm3), and water (100 cm3) were added.  The aqueous layer was then 
separated and washed with petrol ether (30 cm3).  All organic layers were combined, dried 
over MgSO4, filtered and then volatiles evaporated under reduced pressure.  The product 
was a colourless liquid.  Yield 17.8 g, 83 %.  1H-NMR (400 MHz, CDCl3) δ 6.88 (m, 3H), 
4.11 (t, 2H, J = 6.4 Hz), 1.75 (q, 2H, J = 6.9 Hz), 1.46 (m, 2H), 1.32 (m, 4H), 0.90 (t, 3H, J 
= 6.9 Hz).  13C NMR (CDCl3, 400MHz) δC 157.7, 155.2, 136.0, 122.5, 112.2, 112.1, 74.8, 
31.8, 30.0, 25.4, 22.7, 14.0. 
 
6.1.12 Compound 4.20 
To a stirred solution of 2,4-difluor-3-n-hexyloxybenzene (9 g, 42 
mmol) in dry THF (50 cm3) at -78oC, n-butyllithium (1.6 M solution in 
hexane, 31 cm3, 50 mmol) was added slowly.  The solution was 
stirred at -78oC for 2 hours.  Triisopropylborate (14 cm3, 63 mmol) 
was added slowly and the mixture was stirred at -78oC for 1 hour.  
The flask was then left to come up to room temperature whilst stirring for ~19 hours.  The 
mixture was then acidified by the addition of 1M aqueous hydrochloric acid (50 cm3).  The 
mixture was separated and the organic layer was washed with brine (20 cm3) then water 
(10 cm3).  All volatiles were then reduced by rotary evaporation under reduced pressure.  
The residue was then treated with petroleum ether (40 cm3) and left standing at room 
temperature for 2 hours.  The solid formed was then filtered off, washed with petroleum 
ether and dried.  Yield 9.56 g, 89%.  1H-NMR (400 MHz, CDCl3) δ 7.47 (q, 1H, J = 6.9 
Hz), 6.93 (ddd, 1H, J = 11.9, 1.8 Hz), 4.92 (d, 2H, J = 6.4 Hz), 4.09 (t, 2H, J = 6.4 Hz), 
1.74 (q, 2H, J = 6.9 Hz), 1.49-1.42 (m, 2H), 1.33-1.30 (m, 4H), 0.91-0.88 (m, 3H).  13C-
NMR (CDCl3, 400MHz) δC 157.4, 135.2, 129.9, 122.5, 112.9, 112.2, 31.6, 29.9, 26.6, 25.4, 
22.6, 14.1. 
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6.1.13 Compound 4.21 
Potassium phosphate (8.2 g, 38.7 mmol) was dissolved in 
water (20 cm3) and the solution was degassed by bubbling 
nitrogen through the mixture for 10 minutes.  A mixture of 
[2,4-difluoro-3-(hexyloxy)phenyl]boronic acid (5 g, 19.4 
mmol), 4-tert-butyl-2-chloropyridine (2.2 g, 12.9 mmol) and 
1,4-dioxane (60 cm3) was degassed for 10 minutes.  Tetrakis(triphosphine)palladium(0) 
(889 mg, 0.77 mmol) and the solution of K3PO4 was then added and degassed for a 
further 15 minutes.  The solution was then stirred under nitrogen at 105oC for 24 hours.  
Toluene (10 cm3) was added and the aqueous layer was removed.  The organic layer was 
evaporated to dryness by rotary evaporation under reduced pressure.  The product was 
then purified by column chromatography (silica gel, petroleum ether/ethyl acetate 5:1).  
Yield 3.54 g, 78%.  1H-NMR (400 MHz, CDCl3) δ 8.57 (1H, d, J = 5.04 Hz), 7.69-7.67 (1H, 
s), 7.55 (1H, q, J = 8.70, 5.95, 2.75 Hz), 7.22 (1H, dd, J = 5.04, 1.83 Hz), 6.96 (1H, ddd, J 
= 10.07, 8.70, 1.83 Hz), 4.14 (2H, t, J = 6.87 Hz), 1.80-1.70 (2H, m), 1.50-1.41 (2H, m), 
1.34-1.27 (13H, s), 0.89-0.84 (3H, m).  13C NMR (CDCl3, 400MHz) δC 157.71, 155.24, 
136.37, 122.41, 112.09, 40.39, 30.23, 29.23, 23.59, 23.12, 14.07, 10.99. 
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6.1.14 Compound 4.23 
To a stirred solution of 4-tert-butyl-2-[2,4-difluoro-3-
(hexyloxy)phenyl]pyridine (2.7 g, 7.8 mmol) and N, N, N’, 
N’’, N’’-pentamethyldiethylenetriamine (1.4 g, 8.6 mmol) in 
dry THF (50 cm3) at -78oC, n-butyllithium (1.6 M solution in 
hexane, 5 cm3, 8.6 mmol) was added slowly.  The solution 
was stirred at -78oC for 2 hours.  Triisopropylborate (3 cm3, 11.7 mmol) was added slowly 
and the mixture was stirred at -78oC for 1 hour.  The flask was then left to come up to 
room temperature whilst stirring for ~19 hours.  The mixture was then neutralised by the 
addition of 1M aqueous hydrochloric acid (70 cm3).   The aqueous layer was separated 
and the organic layer was washed with brine (20 cm3) then water (10 cm3). Volatiles were 
then removed by rotary evaporation.  The residue was then treated with petroleum ether 
and filtered.  Yield 2.31 g, 76%. 1H-NMR (400 MHz, CDCl3) δ 8.66 (1H, br.s), 7.99 (1H, t, 
J = 15.11, 7.79 Hz), 7.68 (1H, br.s), 7.64 (1H, br.s), 7.27 (1H, br.s), 4.09 (2H, t, J = 12.82, 
6.41 Hz), 1.81-1.71 (2H, m), 1.51-1.40 (2H, m), 1.36-1.23 (13H, m), 0.92-0.80 (3H, m). 
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6.1.15 Compound 4.24 
 A mixture of the boronic acid derivative (1.0 g, 2.6 
mmol), 2-chloro-4-tert-butylpyridine (0.44 g, 2.4 mmol) 
and toluene (30 mL) was deoxygenated by bubbling 
nitrogen through the mixture for 15 minutes. Pd(PPh3)4 
(0.12 g, 0.12 mmol) was added and the mixture was 
additionally deoxygenated by bubbling nitrogen for 5 minutes. Aqueous solution of sodium 
carbonate (2 M, 3.6 mL, 7.2 mmol) was added and the mixture was additionally degassed 
for 5 minutes. The mixture was heated under reflux under nitrogen for 24 hours. Brine (30 
mL) was added and layers were separated. The organic layer was separated, washed 
with brine, dried over anhydrous MgSO4 and filtered. The solvent was removed by rotary 
evaporation under reduced pressure. The product was purified by column 
chromatography using silica gel and a mixture petroleum ether/ethyl acetate, 3/1 as 
eluent. Colorless solid. Yield: 43 %.  1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 5.4 Hz, 2H), 
8.09 (t, J = 8.5 Hz, 1H), 7.69 (br.s, 2H), 7.20 (dd, J = 5.4, 2.1 Hz, 2H), 4.21 (t, J = 7.0 Hz, 
2H), 1.57 (q, J = 7.2 Hz, 2H), 1.34 (m, 6H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 160.53, 154.25 (dd, J = 249.3, 5.6 Hz, C
4, C6), 152.88, 149.72, 136.35 (t, J = 
15.8 Hz, C5), 125.76 (br.s), 125.35 (dd, J = 9.7, 5.7 Hz, C1, C3), 121.54 (t, J = 3.8 Hz, C2), 
75.39, 34.91, 31.65, 30.66, 30.14, 25.47, 22.68, 14.13; 19F NMR (400 MHz): δ -131.3 (d, J 
= 21.5 Hz). 
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6.2 Platinum Complex Synthesis 
6.2.1 Compound 2.7 
 Method A: A solution of potassium tetrachloroplatinate (432 
mg, 1.04 mmol) in water (2 cm3) was added to a stirred solution 
of 4,6-diphenylpyrimidine (120 mg, 0.52 mmol) in acetic acid 
(40 cm3).  The mixture was heated under reflux and N2 at 125
oC 
for 20 hours.  The precipitate was filtered off and washed with acetic acid (10 cm3) and 
ethanol (10 cm3) and dried under vacuum.  The dimer (345 mg, 0.25 mmol), sodium 
acetylacetonate (305 mg, 2.5 mmol) and acetone (50 cm3) was heated under reflux and 
N2 at 70
oC for 22 hours.  The precipitate was filtered and acetone was removed from the 
filtrate by rotary evaporator.  Water (70cm3) was added and the yellow/orange solid was 
filtered.  Yield 70 mg (26%).  1H NMR (CDCl3, 400 MHz) δ 9.59 (1H, d, J = 0.9 Hz), 8.17-
8.11 (2H, m), 7.86 (1H, s), 7.66 (1H, d, J = 7.3), 7.6 (1H, d, J = 7.3 Hz), 7.57-7.50 (3H, m), 
7.28 (1H, ddd, J = 7.3, 7.3, 0.9 Hz), 7.13 (1H, ddd, J = 7.9, 7.8, 1.3 Hz), 5.49 (1H, s), 2.01 
(6H, s).  13C NMR (CDCl3, 400MHz) δ 186.12, 184.00, 174.56, 164.85, 156.07, 142.53, 
135.91, 131.87, 129.17, 127.56, 123.79, 109.07, 102.56, 28.21, 27.19 
 
Method B: A solution of potassium tetrachloroplatinate (200mg, 0.5 mmol) in water (10 
cm3) was added to a solution of tetrabutylammonium bromide (650 mg, 2.0 mmol) in DCM 
(20 cm3).  4,6-diphenylpyrimidine (125 mg, 0.5 mmol) and ethoxyethanol (15 cm3) was 
added and the solution was placed into an oil bath at 100 oC. The solution was purged 
with nitrogen until the DCM had evaporated.  The solution was then left stirring at 100 oC 
for 17 hours.   The precipitate was filtered off and washed with methanol (10 cm3) and 
dried.  The dimer (70 mg, 0.13 mmol), sodium acetylacetonate (159 mg, 1.3 mmol) and 
acetone (50 cm3) was heated under reflux and N2 at 95
oC for 24 hours.  The precipitate 
was filtered and acetone was removed from the filtrate by rotary evaporator.  Water 
(70cm3) was added and the yellow solid was filtered.  Yield 30 mg (11 %).  1H NMR 
(CDCl3, 270 MHz) δ 9.53 (1H, s), 8.14-8.03 (2H, m), 7.80 (1H, s), 7.61-7.45 (5H, m), 7.22 
(1H, t, J = 15.1, 7.2 Hz), 7.07 (1H, t, J = 15.1, 7.7 Hz), 5.43 (1H, s), 1.95 (6H, s). 
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6.2.2 Compound 2.8 
A solution of potassium tetrachloroplatinate (178mg, 0.43 mmol) in 
water (2 cm3) was added to a stirred solution of SK51 (100 mg, 
0.43 mmol) in acetic acid (60 cm3).  The mixture was heated under 
reflux and N2 at 125
oC for 48 hours.  The precipitate was filtered 
off and washed with acetic acid (10 cm3) and ethanol (10 cm3) and 
dried under vacuum.  The dimer (155 mg, 0.17 mmol), sodium acetylacetonate (208 mg, 
1.7 mmol) and acetone (60 cm3) was heated under reflux and N2 at 95
oC for 24 hours.  
The precipitate was filtered and acetone was removed from the filtrate by rotary 
evaporator.  Water (70cm3) was added and the yellow solid was filtered.  Yield 121 mg, 54 
%.  1H NMR (CDCl3, 270MHz) δH 9.41 (1H, s), 8.92 (1H, s), 8.04-7.98 (3H, m), 7.67-7.45 
(4H, m), 7.18-7.09 (2H, m), 5.50 (1H, s), 1.55 (6H, s). 
 
6.2.3 Compound 2.9 
A solution of potassium tetrachloroplatinate (540mg, 1.3 mmol) in 
water (2 cm3) was added to a stirred solution of 2,3-diphenylpyrazine 
(300 mg, 1.3 mmol) in acetic acid (60 cm3).  The mixture was heated 
under reflux and N2 at 125
oC for 15 hours.  The precipitate was filtered 
off and washed with acetic acid (10 cm3) and ethanol (10 cm3) and 
dried under vacuum.  The dimer (578 mg, 0.63 mmol), sodium acetylacetonate (769 mg, 
6.3 mmol) and acetone (70 cm3) was heated under reflux and N2 at 70
oC for 16 hours.  
The precipitate was filtered and acetone was removed from the filtrate by rotary 
evaporator.  Water (70cm3) was added and then residue was filtered and washed in 
acetone.  Yield 590 mg, 78%.  1H NMR (CDCl3, 400MHz) δH 9.11 (1H, d, J = 3.2 Hz), 8.31 
(1H, d, J = 3.2 Hz), 7.64 (1H, d, J = 7.8 Hz), 7.57-7.50 (5H, m), 7.11 (1H, t, J = 8.7 Hz), 
6.71 (1H, t, J = 8.2 Hz), 6.64 (1H, d, J = 6.9 Hz), 5.50 (1H, s), 2.04 (6H, d, J = 4.1 Hz). 
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6.2.4 Compound 2.10 
A solution of potassium tetrachloroplatinate (357mg, 0.86 mmol) in 
water (4 mL) was added to a stirred solution of SK44 (100 mg, 0.43 
mmol) in acetic acid (60 mL).  The mixture was heated under reflux 
and N2 at 125
oC for 20 hours.  The precipitate was filtered off and 
washed with acetic acid (10 mL) and ethanol (10 mL) and dried under 
vacuum.  The dimer (353 mg, 0.3 mmol), sodium acetylacetonate (183 mg, 1.5 mmol) and 
acetone (60 cm3) was heated under reflux and N2 at 95
oC for 24 hours.  The precipitate 
was filtered and acetone was removed from the filtrate by rotary evaporator.  Water 
(70cm3) was added and the yellow solid was filtered.  Yield 56 mg, 27 %.  1H NMR 
(CDCl3, 270MHz) δH 8.63 (1H, d, J = 8.0 Hz), 8.98 (1H, d, J = 3.1 Hz), 8.64 (1H, d, J = 3.0 
Hz), 8.5 (1H, d, J = 8.8 Hz), 8.09 (1H, d, J = 8.0 Hz), 7.63-7.52 (4H, m), 5.46 (1H, s). 2.00 
(6H, d, J = 3.7). 
 
6.2.5 Compound 2.11 
 A solution of potassium tetrachloroplatinate (150mg, 0.36 mmol) in 
water (2 mL) was added to a stirred solution of SK45 (100 mg, 0.36 
mmol) in acetic acid (60 mL).  The mixture was heated under reflux 
and N2 at 125
oC for 24 hours.  The precipitate was filtered off and 
washed with acetic acid (10 mL) and ethanol (10 mL) and dried 
under vacuum.  The dimer (132 mg, 0.13 mmol), sodium acetylacetonate (159 mg, 1.3 
mmol) and acetone (60 cm3) was heated under reflux and N2 at 95
oC for 23 hours.  The 
precipitate was filtered and acetone was removed from the filtrate by rotary evaporator.  
Water (70cm3) was added and the yellow solid was filtered.  Yield 40 mg (19 %).  1H NMR 
(CDCl3, 270MHz) δH 9.97 (1H, d, J = 8.9 Hz), 9.29 (1H, J = 8.4 Hz), 8.47 (1H, d, J = 8.1 
Hz), 8.34 (1H, d, J = 8.3 Hz), 8.09 (1H, d, J = 8.3 Hz), 7.95-7.66 (5H, m), 7.56 (1H, t, J = 
7.8 Hz), 5.62 (2H, s), 2.11 (6H, d, J = 11.1). 
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6.2.6 Compound 2.13 
 A solution of potassium tetrachloroplatinate (1.08 g, 2.6 mmol) in 
water (3 mL) was added to a stirred solution of 2,3-diphenylpyrazine 
(300 mg, 1.3 mmol) in acetic acid (60 mL).  The mixture was heated 
under reflux and N2 at 125
oC for 15 hours.  The precipitate was 
filtered off and washed with acetic acid (10 mL) and ethanol (10 mL) 
and dried under vacuum.  The dimer (500 mg, 0.36 mmol), sodium 
acetylacetonate (440 mg, 3.6 mmol) and acetone (70 cm3) was 
heated under reflux and N2 at 70
oC for 16 hours.  Precipitate was filtered and washed with 
acetone.  Water (70 cm3) was added to residue and then filtered and rinsed with water 
then acetone.  Yield 340 mg (32%).  1H NMR (CDCl3, 270MHz) δH 8.63 (2H, s), 8.03 (2H, 
d, J = 7.9 Hz), 7.67 (2H, d, J = 7.7 Hz), 7.26 (2H, t, J = 6.2 Hz), 7.00 (2H, t, J = 8.2 Hz), 
5.48 (2H, s), 2.05 (6H, s), 2.00 (6H, s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
138 
 
6.2.7 Compound 2.14 and 2.20  
 
 A solution of 
potassium 
tetrachloroplatinate 
(1 g, 2.42 mmol) in 
water (4 cm3) was 
added to a stirred solution of L1H2 (375 mg, 1.61 mmol) in acetic acid (80 cm
3).  The 
mixture was heated at reflux under a nitrogen atmosphere for 3 days.  The precipitate was 
filtered off and washed successively with acetic acid (10 cm3) and ethanol (10 cm3) to give 
the dichlorobridged intermediate.  A mixture of the intermediate (1.07 g, 1.29 mmol), 
2,2,6,6-tetramethyl-3,5-heptanedione (949 mg, 5.16 mmol), aqueous K2CO3 solution (2M, 
5 cm3, 10.32 mmol) and acetone (80 cm3) was heated at reflux under N2 for 24 h.  The 
solvent was removed by rotary evaporation, the residue was treated with DCM, filtered, 
and the filtrate was evaporated to dryness.  The residue was then purified by column 
chromatography using silica gel and a mixture of dichloromethane/hexane, 1/2  as the 
eluent to give both the mononuclear and dinuclear products.  2.14 Rf = 0.1, yield 150 mg, 
15 %.  1H NMR (CDCl3, 400 MHz) δH 9.62 (1H, d, J = 0.9 Hz), 8.17-8.14 (2H, m), 7.90 
(1H, d, J = 0.9 Hz), 7.72 (1H, dd, J = 7.6, 0.8 Hz), 7.64 (1H, dd, J = 7.6, 1.0 Hz), 7.56–
7.54 (3H, m), 7.31 (1H, ddd, J = 7.6, 7.6, 1.0 Hz), 7.15 (1H, ddd, J = 7.6, 7.6, 0.8 Hz), 5.84 
(1H, s), 1.29 (9H, s), 1.28 (9H, s).  HRMS (NSI): m/z 609.2003 [M+H]+. calcld for 
C27H31N2O2Pt m/z 609.2007.  Elemental analysis calcld for C27H30N2O2Pt: C 53.20, H 4.96, 
N 4.60 %; found C 53.31, H 4.92, N 4.49 %.  2.20 Rf = 0.2, yield 29 mg, 1.8 %.  
1H NMR 
(CDCl3, 400 MHz) δH 9.68 (1H, s), 7.71 (2H, br.d, J = 7.6 Hz), 7.70 (1H, s), 7.62 (2H, br.d, 
J = 7.6 Hz), 7.34 (2H, br.t, J = 7.6 Hz), 7.17 (2H, br.t, J = 7.6 Hz), 5.84 (2H, s), 1.28 (18H, 
s) 1.26 (18H, s).  HRMS (NSI): m/z 985.2934 [M+H]+. calcld for C38H48N2O4Pt2H m/z 
985.2941. Elemental analysis calcld for C38H48N2O4Pt2: C 46.24, H 4.90, N 2.84 %; found 
C 46.30, H 5.25, N 2.64%. 
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6.2.8 Compound 2.15 & 2.21 
  A solution of potassium tetrachloroplatinate 
(896 mg, 2.16 mmol) in water (4 cm3) was 
added to a stirred solution of L2H2 (250 mg, 
1.08 mmol) in acetic acid (80 cm3).  The 
mixture was heated at reflux under N2 for 3 
days.  The precipitate was filtered off and 
washed consecutively with acetic acid (10 
cm3) and ethanol (10 cm3) and dried to give the dichlorobridged dimer.  A mixture of the 
dimer (680 mg, 1.32 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione (972 mg, 5.28 mmol), 
aqueous K2CO3 solution (2M, 5 cm
3, 10.56 mmol) and acetone (80 cm3) was heated at 
reflux under N2 for 24 h.  Acetone was removed by rotary evaporation and the residue was 
then washed with water, filtered and dried.  The solid was purified by column 
chromatography using silica gel and dichloromethane as an eluent to give both the 
mononuclear and dinuclear products.  For PtL2H, Rf = 0.6, yield 230 mg, 35 %.  
1H NMR 
(CDCl3, 400 MHz) δH 9.54 (1H, d, J = 1.2 Hz, 
3JH-Pt = 46 Hz), 8.95 (1H, d, J = 1.2 Hz, 
4JH-Pt 
= 13 Hz), 8.06–8.01 (2H, m), 7.70 (1H, dd, J = 7.8, 1.6 Hz), 7.60 (1H, dd, J = 7.8, 1.6 Hz), 
7.58–7.48 (3H, m), 7.29 (1H, ddd, J = 7.4, 7.4, 1.2 Hz), 7.17 (1H, ddd, J = 7.4, 7.4, 1.2 
Hz), 5.86 (1H, s), 1.34 (9H, s), 1.31 (9H, s).  HRMS (NSI): m/z 609.2003 [M+H]+. calcld for 
C27H31N2O2PtH m/z 609.2007. Elemental analysis calcld for C27H30N2O2Pt: C 53.20, H 
4.96, N 4.60 %; found C 52.52, H 4.47, N 4.15 %.  For Pt2L2, Rf = 0.9, yield 150 mg, 15 %.  
1H NMR (CDCl3, 400 MHz) δH 9.44 (2H, s), 7.72 (2H, dd, J = 6.7, 1.5 Hz), 7.43 (2H, dd, J 
= 6.7, 1.5 Hz), 7.29 (2H, ddd, J = 7.7, 7.7, 1.5 Hz), 7.17 (2H, ddd, J = 7.7, 7.7, 1.5 Hz), 
5.88 (2H, s), 1.37 (18H, s), 1.30 (18H, s).  HRMS (NSI): m/z 985.2940 [M+H]+. calcld for 
C38H48N2O4Pt2H m/z 985.2941.  Elemental analysis calcld for C38H48N2O4Pt2: C 46.24, H 
4.90, N 2.84 %; found C 46.36, H 5.27, N 2.60%. 
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6.2.9 Compound 3.4 & 3.7 
  2,5-bis(4-methylphenyl)pyrazine 
(250 mg, 1.02 mmol) and 
potassium tetrachloroplatinate 
(635 mg, 1.53 mmol) were added 
to acetic acid (60 mL).  The 
mixture was heated under reflux 
and N2 at 125
oC for 1 day.  The 
precipitate was filtered off rinsed with acetic acid (10 cm3) dried to give the dichlorobridged 
intermediates.  The dimer (560 mg), 2,2,6,6-tetramethylheptane-3,5-dione (405 mg, 2.2 
mmol), and potassium carbonate (455 mg, 3.3 mmol) and acetone (70 cm3) was heated 
under reflux and N2 at 95
oC for 24 hours. Acetone was removed by rotary evaporator.  
Water (70cm3) was added and the solid was filtered.  The solid was purified by column 
chromatography using silica gel and DCM and Petroleum ether (2:1) as the eluent to give 
both the mono-Pt and di-Pt complexes.  Mononuclear SK95 Rf 0.3.  Yield 40 mg, 6 %.  
Melting point 233-235 °C.  1H NMR (CDCl3, 400 MHz) δ 9.45 (1H, d, J = 1.5 Hz), 8.86 (1H, 
d, J = 1.5 Hz), 7.90 (2H, d, J =  8.3 Hz), 7.48 (1H, s), 7.46 (1H, d, J = 8.1 Hz), 7.33 (2H, d, 
J = 8.5 Hz), 6.96, (1H, dd, J = 8.3, 1.8 Hz), 5.84 (1H, s), 2.43 (3H, s), 2.41 (3H, s), 1.32 
(9H, s), 1.29 (9H, s).  Dinuclear SK95 Rf 0.7.  Yield 13 mg, 1 %.  1H NMR (CDCl3, 400 
MHz) δ 9.34 (2H, s), 7.50 (2H, s), 7.29 (2H, d, J = 7.9 Hz), 6.98 (2H, d, J = 8.2 Hz), 5.86 
(2H, s), 2.43 (6H, s), 1.35 (9H, s), 1.30 (9H, s) 
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6.2.10 Compound 3.5 & 3.8 
2,5-bis(4-methoxyphenyl)pyrazine 
(210 mg, 0.70 mmol) and 
potassium tetrachloroplatinate 
(290 mg, 0.70 mmol) were added 
to acetic acid (60 mL).  The 
mixture was heated under reflux 
and N2 at 125
oC for 3 days.  The 
precipitate was filtered off and dried to give the dichlorobridged dimer.  The dimer (294 
mg, 0.52 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (287 mg, 1.56 mmol), potassium 
carbonate (2M, 1.5 cm3) and acetone (70 cm3) was heated under reflux and N2 at 95
oC for 
24 hours. Acetone was removed by rotary evaporator.  Water (70cm3) was added and the 
solid was filtered.  The solid was purified by column chromatography using silica gel and 
DCM as the eluent to give both the mono-Pt and di-Pt complexes.  Mononuclear SK90 Rf 
0.3.  Yield 162 mg, 35 %.  Melting point 238-239 °C.  1H NMR (CDCl3, 400 MHz) δ 9.33 
(1H, d, J = 1.6 Hz), 8.77 (1H, s), 7.94 (2H, d, J =  8.9 Hz), 7.49 (1H, d, J = 8.6 Hz), 7.22 
(1H, d, J = 2.7 Hz), 7.02 (2H, d, J = 9.1 Hz), 6.72, (1H, dd, J = 8.9, 2.8 Hz), 5.84 (1H, s), 
3.88 (3H, s), 3.87 (3H, s), 1.32 (3H, s), 1.29 (3H, s).  Dinuclear SK90 Rf 0.8.  Yield 21 mg, 
3 %.  1H NMR (CDCl3, 400 MHz) δ 9.19 (2H, s), 7.30 (2H, d, J = 8.6 Hz), 7.23 (2H, d, J = 
2.9 Hz), 6.73 (2H, dd, J = 9.0, 2.8 Hz), 5.85 (2H, s), 3.88 (6H, s), 1.35 (3H, s), 1.29 (3H, s) 
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6.2.11 Compound 3.6 & 3.9 
 
2,5-bis(4-fluorophenyl)pyrazine (250 
mg, 1.00 mmol) and potassium 
tetrachloroplatinate (622 mg, 1.50 
mmol) was added to acetic acid (60 
mL).  The mixture was heated under 
reflux and N2 at 125
oC for 1 day.  The 
acetic acid was evaporated and the 
solid was washed with water, filtered and dried to give the dichlorobridged dimer.  The 
dimer (460 mg, 0.6 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (221 mg, 1.2 mmol), and 
potassium carbonate (249 mg, 1.8 mmol) and acetone (70 cm3) was heated under reflux 
and N2 at 95
oC for 24 hours. Acetone was removed by rotary evaporator and the solid was 
washed with water, filtered and dried.  The solid was purified by column chromatography 
using silica gel and DCM/Petroleum ether (2:1) as the eluent to give both the mono-Pt and 
di-Pt complexes.  The mono-Pt complex had an Rf 0.5, yield 98 mg, 15 %.  1H NMR 
(CDCl3, 400 MHz) δH 9.44 (1H, s), 8.86 (1H, s), 8.02-7.97 (2H, m), 7.61-7.56 (2H, m), 
7.33-7.18 (2H, m), 6.87 (1H, dd, J = 6.9, 2.3 Hz), 5.87 (1H, s), 1.32 (9H, s), 1.29 (9H, s).  
The di-Pt complex had an Rf 0.8, yield 47 mg, 5 %.  1H NMR (CDCl3, 400 MHz) δH 9.32 
(2H, s), 7.40 (2H, t, J = 5.0 Hz), 7.33 (2H, d, J = 9.2 Hz), 6.89 (2H, t, J = 11.5 Hz), 5.88 
(2H, s), 1.35 (18H, s), 1.29 (18H, s). 
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6.2.12 Compound 2.16  
A solution of potassium tetrachloroplatinate (270 mg, 0.65 mmol) in 
water (2 cm3) was added to a stirred solution of L3H2 (150 mg, 0.65 
mmol) in acetic acid (60 cm3).  The mixture was heated at reflux 
under an argon atmosphere for 19 h.  The precipitate was filtered 
off and washed successively with acetic acid (10 cm3) and ethanol 
(10 cm3) and dried to give the dichlorobridged dimer.  A mixture of the dimer (150 mg, 
0.30 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione (166 mg, 0.90 mmol), aqueous K2CO3 
solution (2M, 1 cm3, 1.8 mmol) and ethoxyethanol (70 cm3) was heated at reflux under 
argon for 15 h.  The solvent was evaporated and the solid washed in water (70 cm3).  The 
solid was then filtered, dried, and purified by column chromatography using silica gel and 
dichloromethane as the eluent; Rf = 0.4 yield 140 mg, 35 %.  
1H NMR (CDCl3, 400 MHz) 
δH 9.10 (1H, d, J = 3.4 Hz, 
3JH-Pt = 47 Hz), 8.33 (1H, d, J = 4.5 Hz), 7.69 (1H, dd, J = 7.9, 
1.4 Hz), 7.57–7.49 (5H, m), 7.13 (1H, ddd, J = 7.8, 7.2, 1.8 Hz), 6.75-6.23 (2H, m), 5.84 
(1H, s), 1.29 (9H, s), 1.28 (9H, s).  HRMS (ESI): m/z 609 [M+H]+.  Elemental analysis 
calcld for C27H30N2O2Pt: C 53.20, H 4.96, N 4.60 %; found C 53.64, H 5.18, N 4.52 %. 
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6.2.13 Compound 2.22 
 A solution of potassium tetrachloroplatinate (540 mg, 1.30 mmol) 
in water (4 cm3) was added to a stirred solution of L3H2 (150 mg, 
0.65 mmol) in acetic acid (60 cm3).  The mixture was heated at 
reflux under N2 for 24 h.  The precipitate was filtered off and 
washed successively with acetic acid (10 cm3) and ethanol (10 
cm3) and dried to give the dichlorobridged dimer.  A mixture of the 
dimer (200 mg, 0.26 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione 
(144 mg, 0.78 mmol), aqueous K2CO3 solution (2M, 1 cm
3, 1.56 
mmol) and ethoxyethanol (70 cm3) was heated under reflux under nitrogen for 15 h.  The 
solvent was evaporated and the solid washed with water (70 cm3).  The solid was then 
filtered off and dried.  The product was purified by column chromatography using silica gel 
and dichloromethane as an eluent; Rf = 0.9 yield 60 mg, 9 %.  
1H NMR (CDCl3, 400 MHz) 
δH 8.69 (2H, s), 8.03 (2H, dd, J = 8.5, 2.0 Hz), 7.73 (2H, dd, J = 8.5, 2.0 Hz), 7.31-7.25 
(2H, m), 7.00 (2H, ddd, J = 7.6, 7.8, 1.8 Hz), 5.86 (1H, s), 1.31 (18H, s), 1.30 (18H, s).  
HRMS (ESI): m/z 985 [M+H]+.  Elemental analysis calcld for C38H48N2O4Pt2: C 46.24, H 
4.90, N 2.84 %; found C 46.31, H 5.05, N 2.79 %. 
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6.2.14 Compound 2.17 and 2.22 
A solution of potassium tetrachloroplatinate 
(452 mg, 1.09 mmol) in water (2 cm3) was 
added to a stirred solution of L4H2 (250 mg, 
1.09 mmol) in acetic acid (75 cm3).  The 
mixture was heated at reflux under N2 for 
24 h.  The precipitate was filtered off and 
washed successively with acetic acid (10 
cm3) and ethanol (10 cm3) and dried to give 
the dichlorobridged dimer.  A mixture of the dimer (270 mg, 0.55 mmol), 2,2,6,6-
tetramethyl-3,5-heptanedione (304 mg, 1.65 mmol), aqueous K2CO3 solution (2M, 2 cm
3, 
3.3 mmol) and acetone (70 cm3) was heated under reflux, under N2 for 23 h.  The mixture 
was filtered and water (70 cm3) was added to the filtrate.  The precipitated solid was 
filtered off, washed with water and dried.  The product was then purified by column 
chromatography using silica gel and dichloromethane as the eluent to give both the 
mononuclear and dinuclear products.  For PtL4H, Rf = 0.7, yield 100 mg, 15%.  1H NMR 
(CDCl3, 400 MHz) δH 9.13 (1H, dd, J = 7.7, 1.3 Hz), 9.09 (1H, d, J = 3.4 Hz), 8.75 (1H, d, J 
= 3.4 Hz), 8.60 (1H, dd, J = 8.2, 1.3 Hz), 8.19 (1H, dd, J = 8.2, 1.3 Hz), 7.86–7.63 (4H, m), 
5.91 (1H, s), 1.18, (18H, s).  HRMS (ESI): m/z 607 [M+ H]+.  Elemental analysis calcld for 
C27H28N2O2Pt: C 53.37, H 4.64, N 4.61 %; found C 53.65, H 4.75, N 4.48 %.  For Pt2L
4, Rf 
= 0.9, yield 50 mg, 5 %.  1H NMR (CDCl3, 400 MHz) δH 8.69 (2H, s), 8.09 (2H, d, J = 7.6 
Hz), 7.75 (2H, d, J = 8.4 Hz), 7.62 (2H, t, J = 8.0, 7.6 Hz), 5.91 (2H, s), 1.36 (18H, s), 1.35 
(18H, s).  HRMS (ESI): m/z 982 [M+ H]+.  Elemental analysis calcld for C38H46N2O4Pt: C 
46.69, H 4.95, N 2.81 %; found C 46.86, H 4.87, N 2.82 %. 
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6.2.15 Compound 2.18 
Under N2 atmosphere, L5H2 (220 mg, 0.78 mmol) and potassium 
tetrachloroplatinate (420 mg, 1.01 mmol) were dissolved in acetic 
acid (50 cm3) and the mixture was heated at reflux overnight.  The 
mixture was cooled to room temperature and the black solid was 
filtered off, washed with ethanol (20 cm3) and air dried.  The crude 
product was added to a solution of 2,2,6,6-tetramethyl-3,5-heptanedione (432 mg, 2.34 
mmol) in acetone (60 cm3), followed by aqueous K2CO3 solution (2M, 5 cm3).  The 
mixture was heated at reflux overnight.  Acetone was removed under reduced pressure 
and the crude product was dissolved in DCM.  The organic layer was washed with brine 
and dried with MgSO4.  The solvent was removed under vacuum and the product was 
then purified by column chromatography using silica gel and CHCl3.  Rf = 0.4, yield 231 
mg, 45%.  1H NMR (CDCl3, 400 MHz) δH 9.42 (1H, dd, J = 8.7 Hz, J = 1.4 Hz), 8.08 (1H, 
dd, J = 7.2 Hz, J = 2.2 Hz), 7.85 (1H, dd, J = 7.6 Hz, J = 1.1 Hz), 7.74 (4H, m), 7.54 (3H, 
m), 7.15 (1H, ddd, J = 6.4 Hz, J = 2.3 Hz, J = 2.3 Hz), 6.76 (2H, m), 5.95 (1H, s), 1.33 (9H, 
s), 1.29 (9H, s).  MS (ESI): m/z 659 [M+H]+.  Elemental analysis calcld for 
C31H32N2O2Pt: C 56.44, H 4.89, N 4.25 %; found C 56.84, H 5.12, N 4.08 %.  
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6.2.16 Compound 2.24 
 
Under N2 atmosphere, PtL
5H (200 mg, 0.3 mmol) and potassium 
tetrachloroplatinate (415 mg, 0.36 mmol) were dissolved in acetic 
acid (40 cm3) and the mixture was heated at reflux 15 h. The 
mixture was cooled to room temperature and the black solid was 
filtered off, washed with ethanol (20 cm3) and air dried.  The crude 
product was added to a solution of 2,2,6,6-tetramethyl-3,5-
heptanedione (74 mg, 0.4 mmol) in acetone (50 cm3), followed by 
aqueous K2CO3 solution (2M, 5 cm
3).  The mixture was heated at 
reflux for 16 h.  Acetone was removed under reduced pressure and the crude product 
dissolved in DCM.  The organic layer was washed with brine, dried over MgSO4, filtered 
and evaporated to dryness.  The residue was then purified by column chromatography 
using silica gel and CH3Cl as the eluent to give the product; Rf = 0.8 yield 102 mg, 33%.  
1H NMR (CDCl3, 400 MHz) δH 9.49 (2H, m), 8.00 (2H, br. d, J = 10 Hz), 7.85 (2H, dd, J = 
12.0 Hz, J = 2.4 Hz), 7.64 (2H, m), 7.26 (2H, ddd, J = 12.0 Hz, J = 11.6 Hz, J = 1.6 Hz), 
7.00 (2H, ddd, J = 11.6 Hz, J = 10.4 Hz, J = 2.4 Hz), 5.96 (2H, s), 1.34 (9H, s), 1.28 (9H, 
s).  MS (ESI): m/z 1035 [M+ H]+. Elemental analysis calcld for C42H50N2O4Pt2: C 48.64, H 
4.86, N 2.70 %; found C 48.86, H 5.38, N 2.48 % 
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6.2.17  Compound 2.19 and 2.25 
A mixture of L6H2 (93 mg, 0.33 mmol), 
potassium tetrachloroplatinate (150 
mg, 0.4 mmol) and acetic acid (35 
cm3) were heated at reflux under 
nitrogen for 14 h.  The mixture was 
allowed to cool to room temperature 
and the black solid was filtered off, 
washed with ethanol (20 cm3) and air 
dried.  The crude product was added to a solution of 2,2,6,6-tetramethyl-3,5-heptanedione 
(431 mg, 2.34 mmol) in acetone (60 cm3), followed by aqueous K2CO3 solution (2M, 5 
cm3).  The mixture was heated at reflux for 14 h.  Acetone was removed under reduced 
pressure, and DCM (30 cm3) and brine (15 cm3) were added.  The organic layer was dried 
over MgSO4 and filtered.  The solvent was removed by rotary evaporation and the residue 
was then purified by column chromatography using silica gel and CHCl3 / hexane, 7/3 v/v, 
as the eluent to give both the mononuclear and dinuclear products.  For 2.9 Rf = 0.7, yield 
24 mg, 11%.  1H NMR (CDCl3, 400 MHz) δH 10.07 (1H, dd, J = 8.7 Hz, J = 1.4 Hz), 9.31 
(1H, dd, J = 9.2 Hz, J = 1.4 Hz), 8.50 (1H, d, J = 7.8 Hz), 8.36 (1H, dd, J = 8.7 Hz, J = 1.4 
Hz), 8.12 (1H, d, J = 7.8 Hz), 7.99 (1H, d, J = 6.9 Hz), 7.69-7.92 (4H, m), 7.62 (1H, t, J = 
7.8 Hz), 5.99 (1H, s), 1.38 (9H, s), 1.37 (9H, s).  HRMS (ESI): m/z 657 [M+ H]+.  Elemental 
analysis calcld for C31H30N2O2Pt: C 56.61, H 4.60, N 4.26 %; found C 56.59, H 4.63, N 
4.18 %.  For 2.25 Rf = 0.8, yield 2 mg, 0.6%.  
1H NMR (CDCl3, 400 MHz) δH 10.15 (2H, m), 
8.06 (2H, d, J = 7.8 Hz), 7.96 (2H, d, J = 7.3 Hz), 7.87 (2H, m), 7.61 (2H, t, J = 7.8 Hz), 
5.99 (2H, s), 1.38 (18H, s), 1.37 (18H, s).  HRMS (ESI): m/z 1033 [M+ H]+. 
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6.3 Iridium Complex Synthesis 
6.3.1 Compound 4.26 
A mixture of 4-tert-butyl-2-[3-(4-tert-butylpyridin-2-yl)-5- 
(hexyloxy)phenyl]pyridine (2.1 g, 4.38 mmol), iridium chloride 
trihydrate (1.59 g, 4.38 mmol), ethoxyethanol (90 cm3) and 
water (30 cm3) was heated under reflux for 14 hours.  The solid 
was filtered off washed with water and ethanol to give, after 
drying, an orange solid.  Yield 2.6 g, 80%.   1H NMR (400 MHz, 
CDCl3) δ 8.43 (d, J = 5.9 Hz, 2H), 8.25 (br.s, 2H), 6.96 (dd, J = 5.9, 1.9 Hz, 2H), 4.18 (t, J 
= 6.5 Hz, 2H), 1.89 (m, 2H), 1.58 (m, 2H), 1.49 (s, 18H), 1.42 (m, 4H), 0.95 (t, J = 6.9 Hz, 
3H); 19F NMR (400 MHz): δ -125.1; 13C NMR DEPT135 (100 MHz, CDCl3) δ 153.5(CH), 
120.5 (t, J = 5.6 Hz, CH), 119.9(CH), 75.9(CH2), 31.7(CH2), 30.8 (CH3), 30.1(CH2), 
25.5(CH2), 22.7(CH2), 14.1(CH3) 
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6.3.2 Compound 4.27 
To a mixture of Ir complex 4.26 (370 mg, 0.5 
mmol), the bis NC ligand 4.18 (90 mg, 0.26 
mmol) and toluene (60 mL), silver triflate 
(191 mg, 0.74 mmol, 1.49 eq) was added 
and the reaction mixture was heated under 
reflux for 8 hours. The heating was removed 
and 10 cm3 of 3M HCl was added to a still warm mixture. After stirring for 5 minutes the 
mixture was separated. Organic phase was evaporated and the residue was treated with 
methanol (40 cm3). The solid was filtered off and washed with on filter with methanol. The 
solid was then dissolved in DCM (20 cm3) and gravity filtered through paper filter. To the 
filtrate methanol (40 cm3) was added the volume of the mixture was reduced to 
approximately 10 cm3 using rotary evaporator. The orange solid was filtered off, washed 
with little amount of methanol. Yield 210 mg, 48%.  1H NMR (400 MHz, CDCl3) δ 11.77 (s, 
1H), 8.40 (s,1H), 8.12 (s, 4H), 7.81 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 5.9 Hz, 4H), 6.95 (dd, 
J = 8.0, 1.6 Hz, 2H),  6.92 (dd, J = 5.9, 1.6 Hz, 4H), 6.28 (d, J = 1.6 Hz, 2H), 4.20 (t, J = 
6.5 Hz, 4H), 1.92 (m, 4H), 1.62 (m, 4H), 1.44 (m, 8H), 1.32 (s, 36H), 1.01 (s, 18H), 0.97 (t, 
J = 6.9 Hz, 6H); 19F NMR (400 MHz): δ -126.9; 13C NMR DEPT135 (100 MHz, CDCl3) δ 
160.3(CH), 150.6(CH), 133.1(CH), 125.8(CH), 120.3(CH), 120.0(CH), 119.2(CH), 
105.8(CH), 77.2(CH2), 31.7(CH2), 30.9 (CH3), 30.5(CH3), 30.2(CH2), 25.6(CH2), 22.7(CH2), 
14.1(CH3) 
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6.3.3 Compound 4.28 
To a mixture of Ir complex 4.26 (148 mg, 0.2 
mmol), the bis NC ligand 4.17 (34 mg, 0.1 
mmol) and toluene (25 cm3), silver triflate (77 
mg, 0.3 mmol, 3 eq) was added and the 
reaction mixture was heated under reflux for 
17 hours. The reaction flask was protected 
from light by aluminium foil. The heating was 
removed and 5 cm3 of 2M HCl was added to 
a still warm mixture. Toluene was evaporated 
leaving a suspension of the product in 
aqueous medial. The solid was separated, 
triturated with methanol and filtered.  The solid was then dissolved in DCM (20 cm3) and 
filtered through celite. To the filtrate methanol (40 cm3) was added the volume of the 
mixture was reduced to approximately 10 cm3 using rotary evaporator. The red solid was 
filtered off, washed with little amount of methanol. Yield 112 mg, 64%. The product is light 
sensitive in solution. δ1H NMR (400 MHz, CDCl3) δ 10.77 (s, 2H), 8.40 (s,1H), 8.15 (s, 
4H), 7.89 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 5.9 Hz, 4H), 6.90 (m,6H), 6.18 (d, J = 1.6 Hz, 
2H), 4.23 (t, J = 6.5 Hz, 4H), 1.94 (m, 4H), 1.62 (m, 4H), 1.44 (m, 8H), 1.33 (s, 36H), 1.00 
(s, 18H), 0.97 (t, J = 6.9 Hz, 6H); 19F NMR (400 MHz): δ -126.5 
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6.3.4 Compound 4.29 
 To a mixture of Ir complex 4.26 (148 
mg, 0.1 mmol), the bis NC ligand 4.16 
(34 mg, 0.1 mmol) and toluene (30 
cm3), silver triflate (77 mg, 0.3 mmol, 
3 eq) was added and the reaction 
mixture was heated under reflux for 8 
hours. The heating was removed and 
10 cm3 of 2M HCl was added to a still warm mixture. The mixture was stirred for 5 
minutes. Toluene was evaporated using rotary evaporator leaving behind around 5 cm3 of 
aqueous solution and amorphous solid on sides of the flask. The aqueous solution was 
decanted. To the residue 30 cm3 of methanol was added. The mixture was heated to 
reflux and filtered. To the filtrate, 5 cm3 of saturated solution of KPF6 was added, followed 
by 20 cm3 of water leading to fine precipitate. The mixture was heated to boil then stirred 
at Rt for 10 min. The solid was filtered off, washed with water to give yellow solid. The 
solid was dried in oven at 100 oC for 2 hours. Yield 100 mg. NMR shows that this is a 
mixture of the desired product and unreacted dichlorobridged complex. The product was 
then purified by column chromatography using silicagel as a stationary phase. The column 
was eluted firstly with DCM, followed by a mixture of DCM/MeOH 20/1. Yield 18 mg (10%)   
1H-NMR (400 MHz, CDCl3) δ 8.74 (2H, s), 7.96 (4H, d, J = 5.95 Hz), 7.92 (4H, s), 7.65 
(2H, d, J = 8.70 Hz), 7.02 (4H, dd, J = 6.41, 2.29 Hz), 6.91 (2H, dd, J = 8.24, 1.83 Hz), 
6.03 (2H, d, J = 1.83 Hz), 4.00 (4H, t, J = 13.28, 6.87 Hz), 1.79-1.71 (4H, m), 1.53-1.42 
(4H, m), 1.37-1.27 (8H, m), 1.18 (36H, s), 0.93-0.83 (24H, m).  13C-NMR (101 MHz, 
CDCl3) δ 169.95, 164.68, 163.57, 162.60, 155.95, 154.33, 153.29, 152.60, 141.65, 
139.95, 131.11, 127.26, 127.00, 124.04, 120.68, 120.58, 120.42, 75.49, 35.05, 34.58, 
31.64, 30.84, 30.44, 30.02, 29.78, 25.49, 22.66, 14.10.  19F NMR (400 MHz): δ -125.75. 
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6.4 Miscellaneous 
6.4.1 (4-tert-butylphenyl)boronic acid 
 To a stirred solution of 1-bromo-4-tert butylbenzene (9.7 g, 45.7 mmol) in 
dry THF (80 cm3) at -78oC, n-butyllithium (1.6 M solution in hexane, 30 cm3, 
48 mmol) was added slowly.  The solution was stirred at -78oC for 2 hours.  
Triisopropylborate (16 cm3, 70.5 mmol) was added slowly and the mixture 
was stirred at -78oC for 1 hour.  The flask was then left to come up to room temperature 
whilst stirring for ~19 hours.  The mixture was then acidified by the addition of 1M 
aqueous hydrochloric acid (50 cm3).  Ethyl acetate  was added and the mixture was 
separated.  The organic layer was washed with brine (20 cm3) then water (10 cm3).  All 
volatiles were then reduced by rotary evaporation under reduced pressure.  Yield 6.9 g, 
85%.  1H-NMR (400 MHz, CDCl3) δH 8.16 (2H, d, J = 8.24 Hz), 7.53 (2H, d, J = 8.24 Hz), 
1.37 (9H, s)94. 
 
6.4.2 Tetrakis(triphenylphosphine) palladium (o)  
 Palladium dichloride (1 g, 5.6 mmol), triphenylphosphine (7.4 g, 
28.2 mmol) and dimethyl sulfoxide  (68 mL) were heated to 140 
oC until the solid dissolved.  The solution was then removed 
from the oil bath and left stirring for a further 10 minutes.  
Hydrazine hydrate (1.1 mL) was then rapidly added and the 
solution cooled to ~120oC where crystallisation occurs.  The solution was then removed 
from the water bath and left to cool to room temperature.  The solution was then filtered 
and washed with absolute ethanol (2 x 10 mL) and diethyl ether (2 x 10 mL).  The 
resulting yellow solid was then left to dry for 2 hours.  Yield 6.4 g
95
. 
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6.4.3 Sodium acetylacetonate 
 Metallic sodium (2.1 g, 90 mmol) was dissolved in ethanol (50 cm3).  
Acetylacetone (9 g, 90 mmol) was then added drop wise whilst stirring.  
The solution was then left stirring for 1 hour.  The resulting precipitate was then filtered off.  
Yield 7.2 g.  1H-NMR (270 MHz, CDCl3) δH 5.51 (1H, s), 2.05 (6H, s). 
 
6.4.4 Sodium dipivaloylmethane 
 Metallic sodium (750 mg, 32.6 mmol) was dissolved in ethanol (50 
cm3).  Dipivaloylmethane (6 g, 32.6 mmol) was then added drop wise 
whilst stirring.  The solution was then left stirring for 2 hours.  The resulting precipitate was 
then filtered off.  Yield 6.97 g.  Not soluble for NMR. 
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7 Appendices 
7.1 TD DFT Data 
7.1.1 Complex 2.14 and 2.20 
Table 7.1 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.1 and its mono- and dinuclear complexes
a
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7.1.2 Complex 2.15 and 2.21 
 
Table 7.2 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.2 and its mono- and dinuclear complexes
a
 
 
 
 
 
 
 
 
158 
 
7.1.3 Complex 2.16 and 2.22 
 
Table 7.3 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.3 and its mono- and dinuclear complexes
a
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7.1.4 Complex 2.17 and 2.23 
 
Table 7.4 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.4 and its mono- and dinuclear complexes
a
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7.1.5 Complex 2.18 and 2.24 
 
Table 7.5 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.5 and its mono- and dinuclear complexes
a
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7.1.6 Complex 2.19 and 2.25 
 
Table 7.6 Selected calculated excitation energies (ΔE), oscillator strengths (f), and main orbital 
components for the proligand 2.6 and its mono- and dinuclear complexes
a
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7.2 Calculated frontier orbital energies 
Table 7.7 Calculated Frontier Orbital Energies (eV, in vacuo) for the Complexes 
Complex 2.14 2.20 2.15 2.21 2.16 2.22 2.17 2.23 2.18 2.24 2.19 2.24 
LUMO+2 -1.296 -1.416 -1.380 -1.471 -1.359 -1.447 -1.399 -1.451 -1.357 -1.420 -1.415 -1.461 
LUMO+1 -1.714 -1.926 -1.791 -1.953 -1.799 -2.186 -1.651 -1.672 -1.708 -2.085 -1.512 -1.500 
LUMO -2.396 -2.633 -2.426 -2.764 -2.311 -2.684 -2.515 -2.854 -2.629 -2.889 -2.834 -3.095 
HOMO -5.816 -5.828 -5.824 -5.789 -5.801 -5.793 -5.807 -5.794 -5.817 -5.822 -5.809 -5.751 
HOMO-1 -6.133 -6.005 -6.194 -6.036 -6.194 -5.971 -6.239 -5.871 -6.093 -5.968 -6.145 -5.897 
HOMO-2 -6.301 -6.114 -6.415 -6.159 -6.388 -6.247 -6.412 -6.268 -6.352 -6.139 -6.378 -6.179 
HOMO-LUMO gap 3.420 3.196 3.397 3.025 3.490 3.109 3.292 2.940 3.188 2.933 2.976 2.65 
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7.3 Frontier orbital plots 
7.3.1 Complex 2.14 and 2.20 
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7.3.2 Complex 2.15 and 2.21 
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7.3.3 Complex 2.16 and 2.22 
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7.3.4 Complex 2.17 and 2.23 
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7.3.5 Complex 2.18 and 2.24 
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7.3.6 Complex 2.19 and 2.25 
 
 
  
169 
 
 
 
 
 
 
References 
  
170 
 
 
References 
(1)  Qiao, J.; Duan, L.; Tang, L.; He, L.; Wang, L.; Qiu, Y. J. Mater. Chem. 2009, 19, 
6573. 
(2)  Thorp-Greenwood, F.; Balasingham, R. G. J. Organomet. Chem. 2012, 714, 12–21. 
(3)  Zhao, Q.; Huang, C.; Li, F. Chem. Soc. Rev. 2011, 40, 2508–2524. 
(4)  Li, C.; Lin, J.; Yang, X.; Wan, J. J. Organomet. Chem. 2011, 696, 2445–2450. 
(5)  Anthopoulos, T. D.; Frampton, M. J.; Namdas, E. B.; Burn, P. L.; Samuel, I. D. W. 
Adv. Mater. 2004, 16, 557–560. 
(6)  Williams, J. A. G. Top. Curr. Chem. 2007, 281, 205–268. 
(7)  Kozhevnikov, D. N.; Kozhevnikov, V. N.; Ustinova, M. M.; Santoro, A.; Bruce, D. 
W.; Koenig, B.; Czerwieniec, R.; Fischer, T.; Zabel, M.; Yersin, H. Inorg. Chem. 
2009, 48, 4179–4189. 
(8)  Brooks, J.; Babayan, Y.; Lamansky, S.; Djurovich, P. I.; Tsyba, I.; Bau, R.; 
Thompson, M. E. Inorg. Chem. 2002, 41, 3055–3066. 
(9)  Laskar, I. R.; Hsu, S.-F.; Chen, T.-M. Polyhedron 2005, 24, 881–888. 
(10)  Borisov, S. M.; Klimant, I. Dye. Pigment. 2009, 83, 312–316. 
(11)  Duan, J.-P.; Sun, P.-P.; Cheng, C.-H. Adv. Mater. 2003, 15, 224–228. 
(12)  Nazeeruddin, K.; Humphry-Baker, R.; Berner, D.; Rivier, S.; Zuppiroli, L.; Graetzel, 
M. J. Am. Chem. Soc. 2003, 125, 8790–8797. 
(13)  Nonoyama, M. Bull. Chem. Soc. Jpn. 1974, 47, 767–768. 
(14)  Hwang, F.-M.; Chen, H.-Y.; Chen, P.-S.; Liu, C.-S.; Chi, Y.; Shu, C.-F.; Wu, F.-I.; 
Chou, P.-T.; Peng, S.-M.; Lee, G.-H. Inorg. Chem. 2005, 44, 1344–1353. 
(15)  Li, M.; Zeng, H.; Meng, Y.; Sun, H.; Liu, S.; Lu, Z.; Huang, Y.; Pu, X. Dalt. Trans. 
2011, 40, 7153–7164. 
(16)  King, K. A.; Spellane, P. J.; Watts, R. J. J. Am. Chem. Soc. 1985, 1431–1432. 
(17)  Sprouse, S.; King, K. A.; Spellane, P. J.; Watts, R. J. J. Am. Chem. Soc. 1984, 106, 
6647–6653. 
(18)  Tsuboyama, A.; Iwawaki, H.; Furugori, M.; Mukaide, T.; Kamatani, J.; Igawa, S.; 
Moriyama, T.; Miura, S.; Takiguchi, T.; Okada, S.; Hoshino, M.; Ueno, K. J. Am. 
Chem. Soc. 2003, 125, 12971–12979. 
171 
 
(19)  Dedeian, K.; Djurovich, P. I.; Garces, F. O.; Carlson, G.; Watts, R. J. Inorg. Chem. 
1991, 1685–1687. 
(20)  Williams, J. A. G.; Beeby, A.; Davies, E. S.; Weinstein, J. A.; Wilson, C. Inorg. 
Chem. 2003, 42, 8609–8611. 
(21)  Williams, J. A. G.; Beeby, A.; Davies, E. S.; Weinstein, J. A.; Wilson, C. Inorg. 
Chem. 2003, 42, 8609–8611. 
(22)  Cardenas, D. J.; Echavarren, A. M.; Ramırez de Arellano, M. C. Organometallics 
1999, 18, 3337–3341. 
(23)  Brulatti, P.; Gildea, R. J.; Howard, J. A. K.; Fattori, V.; Cocchi, M.; Williams, J. A. G. 
Inorg. Chem. 2012, 51, 3813–3826. 
(24)  Wilkinson, A. J.; Puschmann, H.; Howard, J. A. K.; Foster, C. E.; Williams, J. A. G. 
Inorg. Chem. 2006, 45, 8685–8699. 
(25)  Flynn, C. M.; Demas, J. N. J. Am. Chem. Soc. 1973, 96, 1959–1960. 
(26)  Collin, J. P.; Dixon, I. M.; Sauvage, J. P.; Williams, J. A. G.; Barigelletti, F.; 
Flamigni, L. J. Am. Chem. Soc. 1999, 121, 5009–5016. 
(27)  Hay, P. J. J. Phys. Chem. A 2002, 106, 1634–1641. 
(28)  Kang, H. J.; Lee, K. H.; Lee, S. J.; Seo, J. H.; Kim, Y. K.; Yoon, S. S. Thin Solid 
Films 2011, 519, 6544–6549. 
(29)  Lu, W.; Mi, B.-X.; Chan, M. C. W.; Hui, Z.; Che, C.-M.; Zhu, N.; Lee, S.-T. J. Am. 
Chem. Soc. 2004, 126, 4958–4971. 
(30)  Lamansky, S.; Djurovich, P.; Murphy, D.; Abdel-Razzaq, F.; Kwong, R.; Tsyba, I.; 
Bortz, M.; Mui, B.; Bau, R.; Thompson, M. E. Inorg. Chem. 2001, 40, 1704–1711. 
(31)  Laskar, I. R.; Chen, T.-M. Chem. Mater. 2004, 16, 111–117. 
(32)  Lee, K. H.; Kang, H. J.; Lee, S. J.; Seo, J. H.; Kim, Y. K.; Yoon, S. S. Synth. Met. 
2011, 161, 1113–1121. 
(33)  Lee, K. H.; Kang, H. J.; Lee, S. J.; Kim, Y. K.; Yoon, S. S. Synth. Met. 2012, 162, 
715–721. 
(34)  Zhou, G.; Ho, C.-L.; Wong, W.-Y.; Wang, Q.; Ma, D.; Wang, L.; Lin, Z.; Marder, T. 
B.; Beeby, A. Adv. Funct. Mater. 2008, 18, 499–511. 
(35)  Lepeltier, M.; Dumur, F.; Wantz, G.; Vila, N.; Mbomekallé, I.; Bertin, D.; Gigmes, D.; 
Mayer, C. R. J. Lumin. 2013, 143, 145–149. 
(36)  Dahule, H. K.; Dhoble, S. J.; Ahn, J.-S.; Pode, R. J. Phys. Chem. Solids 2011, 72, 
1524–1528. 
(37)  Kim, K. H.; Lee, J. Y.; Park, T. J.; Jeon, W. S.; Kennedy, G. P.; Kwon, J. H. Synth. 
Met. 2010, 160, 631–635. 
(38)  Yang, C.-H.; Tai, C.-C.; Sun, I.-W. J. Mater. Chem. 2004, 14, 947. 
172 
 
(39)  Tao, R.; Qiao, J.; Zhang, G.; Duan, L.; Wang, L.; Qiu, Y. J. Phys. Chem. C 2012, 
116, 11658–11664. 
(40)  Jiang, J.; Jiang, C.; Yang, W.; Zhen, H.; Huang, F.; Cao, Y. Macromolecules 2005, 
38, 4072–4080. 
(41)  Kozhevnikov, D. N.; Kozhevnikov, V. N.; Shafikov, M. Z.; Prokhorov, A. M.; Bruce, 
D. W.; Williams, J. A. G. Inorg. Chem. 2011, 50, 3804–3815. 
(42)  Obara, S.; Itabashi, M.; Okuda, F.; Tamaki, S.; Tanabe, Y.; Ishii, Y.; Nozaki, K.; 
Haga, M.-A. Inorg. Chem. 2006, 45, 8907–8921. 
(43)  Kozhevnikov, V. N.; Durrant, M. C.; Williams, J. A. G. Inorg. Chem. 2011, 50, 6304–
6313. 
(44)  Tsujimoto, H.; Yagi, S.; Asuka, H.; Inui, Y.; Ikawa, S.; Maeda, T.; Nakazumi, H.; 
Sakurai, Y. J. Organomet. Chem. 2010, 695, 1972–1978. 
(45)  Campbell, N. A.; Reece, J. B. Biology; 7th ed.; Pearson Benjamin Cummings: San 
Fransisco, 2005; pp. 94–123. 
(46)  Fernández-Moreira, V.; Thorp-Greenwood, F. L.; Coogan, M. P. Chem. Commun. 
(Camb). 2010, 46, 186–202. 
(47)  Molecular Probes Handbook, A Guide to Fluorescent Probes and Labelling 
Techniques; Johnson, I.; Spence, M. T. Z., Eds.; 11th ed.; Invitrogen Molecular 
Probes. 
(48)  Elmes, R. B. P.; Orange, K. N.; Cloonan, S. M.; Williams, D. C.; Gunnlaugsson, T. 
J. Am. Chem. Soc. 2011, 133, 15862–15865. 
(49)  Kobayashi, H.; Ogawa, M.; Alford, R.; Choyke, P. L.; Urano, Y. Chem. Rev. 2010, 
110, 2620–2640. 
(50)  Photochemistry and Photophysics of Coordination Compounds; Balzani, V.; 
Campagna, S., Eds.; Springer, 2007; p. 1. 
(51)  Botchway, S. W.; Charnley, M.; Haycock, J. W.; Parker, A. W.; Rochester, D. L.; 
Weinstein, J. a; Williams, J. a G. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16071–
16076. 
(52)  Zipfel, W. R.; Williams, R. M.; Webb, W. W. Nat. Biotechnol. 2003, 21, 1369–1377. 
(53)  Zhao, Q.; Yu, M.; Shi, L.; Liu, S.; Li, C.; Shi, M.; Zhou, Z.; Huang, C.; Li, F. 
Organometallics 2010, 29, 1085–1091. 
(54)  Jiang, W.; Gao, Y.; Sun, Y.; Ding, F.; Xu, Y.; Bian, Z.; Li, F.; Bian, J.; Huang, C. 
Inorg. Chem. 2010, 49, 3252–3260. 
(55)  Lo, K.; Lee, P. Organometallics 2008, 2998–3006. 
(56)  Wu, P.; Wong, E. L.-M.; Ma, D.-L.; Tong, G. S.-M.; Ng, K.-M.; Che, C.-M. Chemistry 
2009, 15, 3652–3656. 
(57)  Eryazici, I.; Moorefield, C. N.; Newkome, G. R. Chem. Rev. 2008, 108, 1834–1895. 
173 
 
(58)  Koo, C.-K.; Wong, K.-L.; Man, C. W.-Y.; Lam, Y.-W.; So, L. K.-Y.; Tam, H.-L.; Tsao, 
S.-W.; Cheah, K.-W.; Lau, K.-C.; Yang, Y.-Y.; Chen, J.-C.; Lam, M. H.-W. Inorg. 
Chem. 2009, 48, 872–878. 
(59)  Koo, C.-K.; So, L. K.-Y.; Wong, K.-L.; Ho, Y.-M.; Lam, Y.-W.; Lam, M. H.-W.; 
Cheah, K.-W.; Cheng, C. C.-W.; Kwok, W.-M. Chemistry 2010, 16, 3942–3950. 
(60)  Lo, K. K.-W.; Louie, M.-W.; Zhang, K. Y. Coord. Chem. Rev. 2010, 254, 2603–
2622. 
(61)  Chen, H.; Zhao, Q.; Wu, Y.; Li, F.; Yang, H.; Yi, T.; Huang, C. Inorg. Chem. 2007, 
46, 11075–11081. 
(62)  Yu, M.; Zhao, Q.; Shi, L.; Li, F.; Zhou, Z.; Yang, H.; Yi, T.; Huang, C. Chem. 
Commun. 2008, 2115–2117. 
(63)  Quick guide to HeLa cells http://www.wellcome.ac.uk/Education-
resources/Education-and-learning/Big-Picture/All-issues/The-
Cell/WTDV030785.htm (accessed Sep 19, 2013). 
(64)  Zhang, K. Y.; Li, S. P.-Y.; Zhu, N.; Or, I. W.-S.; Cheung, M. S.-H.; Lam, Y.-W.; Lo, 
K. K.-W. Inorg. Chem. 2010, 49, 2530–2540. 
(65)  Li, S. P.-Y.; Liu, H.-W.; Zhang, K. Y.; Lo, K. K.-W. Chemistry 2010, 16, 8329–8339. 
(66)  Murphy, L.; Congreve, A.; Pålsson, L.-O.; Williams, J. A. G. Chem. Commun. 2010, 
46, 8743–8745. 
(67)  Zhang, K. Y.; Liu, H.-W.; Fong, T. T.-H.; Chen, X.-G.; Lo, K. K.-W. Inorg. Chem. 
2010, 49, 5432–5443. 
(68)  Moromizato, S.; Hisamatsu, Y.; Suzuki, T.; Matsuo, Y.; Abe, R.; Aoki, S. Inorg. 
Chem. 2012, 51, 12697–12706. 
(69)  Aoki, S.; Matsuo, Y.; Ogura, S.; Ohwada, H.; Hisamatsu, Y.; Moromizato, S.; Shiro, 
M.; Kitamura, M. Inorg. Chem. 2011, 50, 806–818. 
(70)  Kalinowski, J.; Fattori, V.; Cocchi, M.; Williams, J. A. G. Coord. Chem. Rev. 2011, 
255, 2401–2425. 
(71)  Ortmans, I.; Didier, P.; Kirsch-De Mesmaeker, a. Inorg. Chem. 1995, 34, 3695–
3704. 
(72)  Liu, Z. W.; Guan, M.; Bian, Z. Q.; Nie, D. B.; Gong, Z. L.; Li, Z. B.; Huang, C. H. 
Adv. Funct. Mater. 2006, 16, 1441–1448. 
(73)  Hudson, Z. M.; Blight, B. A.; Wang, S. Org. Lett. 2012, 14, 1700–1703. 
(74)  Mason, A. T. Berichte der Dtsch. Chem. Gesellschaft 1886, 19, 112–113. 
(75)  Minsky, A.; Cohen, Y.; Rabinovitz, M. J. Am. Chem. Soc. 1985, 107, 1501–1505. 
(76)  Tsujimoto, H.; Yagi, S.; Asuka, H.; Inui, Y.; Ikawa, S.; Maeda, T.; Nakazumi, H.; 
Sakurai, Y. J. Organomet. Chem. 2010, 695, 1972–1978. 
(77)  Wong, W.-Y.; Ho, C.-L. J. Mater. Chem. 2009, 19, 4457. 
174 
 
(78)  Balashev, K. P.; Puzyk, M. V; Kotlyar, V. S.; Kulikova, M. V. Coord. Chem. Rev. 
1997, 159, 109–120. 
(79)  Yin, B.; Niemeyer, F.; Williams, J. A. G.; Jiang, J.; Boucekkine, A.; Toupet, L.; Le 
Bozec, H.; Guerchais, V. Inorg. Chem. 2006, 45, 8584–8596. 
(80)  Lamansky, S.; Djurovich, P.; Murphy, D.; Abdel-Razzaq, F.; Lee, H. E.; Adachi, C.; 
Burrows, P. E.; Forrest, S. R.; Thompson, M. E. J. Am. Chem. Soc. 2001, 123, 
4304–4312. 
(81)  Bronstein, H. A.; Finlayson, C. E.; Kirov, K. R.; Friend, R. H.; Williams, C. K. 
Organometallics 2008, 27, 2980–2989. 
(82)  Becke, A. D. J. Chem. Phys. 1993, 98, 5648–5652. 
(83)  Hay, P. J.; Watt, W. R. J. Chem. Phys. 1985, 82, 270–284. 
(84)  Cossi, M.; Scalmani, G.; Rega, N.; Barone, V. J. Chem. Phys. 2002, 117, 43–55. 
(85)  Gabriel, S. Berichte der Dtsch. Chem. Gesellschaft 1908, 41, 1127–1156. 
(86)  Gabriel, S. Berichte der Dtsch. Chem. Gesellschaft 1913, 46, 3859–3861. 
(87)  Gildea, L. F.; Batsanov, A. S.; Williams, J. A. G. Dalt. Trans. 2013, 42, 10388–
10393. 
(88)  Tsuboyama, A.; Takiguchi, T.; Okada, S.; Osawa, M.; Hoshino, M.; Ueno, K. Dalt. 
Trans. 2004, 1115–1116. 
(89)  Slater, J.; Rourke, J. P. J. Organomet. Chem. 2003, 688, 112–120. 
(90)  Qing, F.; Ruowen Wang; Li, B.; Zheng, X.; Meng, W. J. Fluor. Chem. 2003, 120, 
21–24. 
(91)  Patil, R. D.; Joshi, G.; Adimurthy, S.; Ranu, B. C. Tetrahedron Lett. 2009, 50, 2529–
2532. 
(92)  Utsukihara, T.; Nakamura, H.; Watanabe, M.; Akira Horiuchi, C. Tetrahedron Lett. 
2006, 47, 9359–9364. 
(93)  Macharla, A. K.; Chozhiyath Nappunni, R.; Marri, M. R.; Peraka, S.; Nama, N. 
Tetrahedron Lett. 2012, 53, 191–195. 
(94)  Balaganesan, B.; Shen, W.; Chen, C. H. Tetrahedron Lett. 2003, 44, 5747–5750. 
(95)  Coulson, D. R.; Satek, L. C.; Grim, S. O. Inorg. Synth. 1972, 13, 121.  
 
